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ABSTRACT  
  
HIV/AIDS is the sixth leading cause of death worldwide and the leading 
cause of death among women of reproductive age living in low-income countries. 
Clinicians in industrialized nations monitor the efficacy of antiretroviral drugs and 
HIV disease progression with the HIV-1 viral load assay, which measures the 
copy number of HIV-1 RNA in blood. However, viral load assays are not widely 
available in sub-Saharan Africa and cost between 50-$139 USD per test on 
average where available.  
To address this problem, a mixed-methods approach was undertaken to 
design a novel and inexpensive viral load diagnostic for HIV-1 and to evaluate 
barriers to its adoption in a developing country. The assay was produced based on 
loop-mediated isothermal amplification (LAMP). Blood samples from twenty-one 
individuals were spiked with varying concentrations of HIV-1 RNA to evaluate 
the sensitivity and specificity of LAMP. Under isothermal conditions, LAMP was 
performed with an initial reverse-transcription step (RT-LAMP) and primers 
designed for HIV-1 subtype C. Each reaction generated up to a few billion copies 
of target DNA within an hour.  Presence of target was detected through naked-eye 
observation of a fluorescent indicator and verified by DNA gel electrophoresis 
and real-time fluorescence. The assay successfully detected the presence of HIV 
in samples with a broad range of HIV RNA concentration, from over 120,000 
copies/reaction to 120 copies/reaction.  
In order to better understand barriers to adoption of LAMP in developing 
countries, a feasibility study was undertaken in Tanzania, a low-income country 
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facing significant problems in healthcare.  Medical professionals in Northern 
Tanzania were surveyed for feedback regarding perspectives of current HIV 
assays, patient treatment strategies, availability of treatment, treatment priorities, 
HIV transmission, and barriers to adoption of the HIV-1 LAMP assay.  
The majority of medical providers surveyed indicated that the proposed 
LAMP assay is too expensive for their patient populations. Significant gender 
differences were observed in response to some survey questions. Female medical 
providers were more likely to cite stigma as a source problem of the HIV 
epidemic than male medical providers while males were more likely to cite lack 
of education as a source problem than female medical providers.  
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INTRODUCTION 
Overview. Human Immunodeficiency Virus (HIV) is responsible for the 
death of more people than any other viral epidemic in recent history.  Among the 
worst pandemics in recorded history was the 1918 “Spanish” pandemic influenza, 
which killed between 20-40 million people (112).  In comparison, it is estimated 
that 24 million people died as a result of HIV infection between 1980-2007 (17).  
There are currently estimated to be 33.3 million people infected with HIV and it 
has been projected that by 2030 the cumulative total will reach 75 million deaths 
(17, 134). It is clear that the vast majority of the over 30 million people currently 
infected with HIV will die as a consequence of infection unless a cure can be 
discovered (134). The highest HIV prevalence rates in the world are found in 
developing nations and in particular, in sub-Saharan Africa, where about 12% of 
the world’s population bears about 70% of the global burden of HIV disease and 
national prevalence rates have reached as high as 38% (135). 
HIV was first noticed in the early 1980s in the United States as a 
consequence of the immune condition it causes, acquired immune deficiency 
syndrome (AIDS). It was discovered that HIV develops a long-term persistent 
infection in immune cells and thereby destroys immune capacity. This creates a 
cycle during which it is estimated that about a billion immune cells are lost per 
day while HIV maintains steady state levels of replication (64).   
The loss of immune cells over many years creates the conditions for 
immune deficiency.  In the absence of a strong immune response, pathogens that 
are otherwise innocuous can cause life-threatening infections.  These so-called 
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opportunistic infections (OIs) are the cause of death for the majority of people 
suffering from AIDS.  
There is no cure for HIV and the availability of an effective vaccine is still 
not on the horizon.  However, antiretroviral (ARV) drug treatments have been 
developed that extend life for people living with HIV and AIDS (PLWHA).  
Because HIV mutates rapidly, ARV monotherapy rapidly evolves drug-resistant 
HIV.  Consequently, ARVs must be administered in multidrug combination 
cocktails (known as cART) in order to effectively suppress HIV replication. 
Because HIV replication is necessary and sufficient for the development of drug-
resistance, sub-optimal (less than 90-95%) adherence to cART has been shown to 
create the conditions for drug-resistant HIV (11, 51, 111). Stigma, toxicity, and 
barriers to regular access of cART can make disciplined adherence difficult in 
developing countries (40, 51, 114). Limited resources, including fewer drug 
options make an outbreak of cART-resistant HIV a serious public health threat for 
developing countries. 
The only reliable method for detecting virologic failure is to measure the 
amount of viral RNA present in blood. This is currently accomplished using a 
clinical diagnostic known as the viral load test. The viral load test is a research 
assay adapted for clinical use in the absence of a feasible alternative.  There are 
currently 3 FDA-approved viral load assays on the market.  Each assay costs over 
$50 USD per test result and requires over $50,000 in equipment capital 
investment, skilled technicians, a large working space, and uninterrupted power, 
making the assay unsuitable for use in developing countries (41, 46).    
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Viral load capacity is a critical issue for developing countries, not only for 
adherence but also for resistance surveillance and improved patient outcomes.  
Consequently, there is an international effort in support of reduced reagent pricing 
from manufacturers and alternative technologies.  An inexpensive viral load test 
suitable for low-resource settings that could be made widely accessible would 
revolutionize patient care for PLWHA in developing countries.  
HIV Epidemiology. An important aspect of HIV epidemiology is the 
significant genetic variability of HIV.  There are two types of HIV: HIV-1 and 
HIV-2. Genetic analyses indicate that each type of HIV originated in central 
Africa from distinct zoonotic transmission events that likely involved more than 
one species of primate (95). Current data indicates that HIV-2 resulted from the 
zoonotic transmission of SIVsmm from a sooty mangabey to a human and HIV-1 
was transmitted to humans from SIVcpz infection in chimpanzees (pan troglodyte 
troglodyte) (24, 50). While HIV-2 largely remains segregated to west and central 
Africa, the vast majority of global HIV prevalence results from HIV-1 infection 
(28, 134). HIV-1 can be separated into three groups: HIV-1 group M (‘major’), O 
(‘outlier’), and N (‘non-M or O’).  HIV-1 group M viruses are the most 
geographically diverse of the groups and account for the majority of HIV-1 
infections globally. 
HIV-1 group M viruses feature genetic variability such that 9 distinct 
clades and several circulating recombinant forms (CRFs) have been identified.  
The major subtypes include HIV-1 group M clades A, B, C, D, F, G, H, J, and K 
(95). Interestingly, all of the HIV-1 group M clades can be found in West and 
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central Africa, while subtype B accounts for the majority of HIV infections in 
North America and Europe (134).  Studies of HIV prevalence between 2000-2007 
indicate that clade C virus accounts for 48% of worldwide infections (63).  HIV-1 
subtype C is found in many of the highest prevalence regions in the world: 
southern Africa, India, and southern Asia.  Any useful diagnostic for HIV-1 must 
account for the extraordinary genetic variability of HIV, the global predominance 
of clade C, and high recombination frequencies that continue to generate 
numerous CRFs.  Moreover, a novel diagnostic for HIV must be accepted by 
communities living and working in the areas of the world where HIV-1 subtype C 
is the predominant species of virus in circulation.  
HIV Transmission. HIV is transmitted sexually, through exposure to 
infected blood, and as a result of mother-to-child transmission. The predominant 
mode of HIV transmission varies widely by geographic region and socioeconomic 
status and these factors have been implicated in the global epidemiology of HIV. 
The vast majority of global HIV transmission occurs as a result of sexual contact 
with infected partners (134).  
Additionally, biological factors play a significant role in sexual 
transmission of HIV. Receptive partners are generally at higher risk for HIV 
infection than insertive partners.  Women are twice as likely as men to be infected 
with HIV through vaginal sex. With regard to anal sex, receptive partners are 5-10 
times more likely to be infected than their circumcised insertive partners. HIV 
transmission is about 8 times more likely to occur during early or late infection 
than during the asymptomatic period of infection because viral load is high during 
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these periods. Additionally, the presence of an ulcerative STI increases the rate of 
sexual HIV transmission by 5.3 times. (31, 47, 139). 
Blood-based transmission largely occurs as a result of injection drug use 
(IDU). IDU represents a significant mode of transmission in industrialized 
nations, but not in developing countries, where access to injection drugs is 
growing but still limited significantly by poverty (3).  IDU contributes to sexual 
transmission of HIV, where a person who uses injection drugs may become 
infected with HIV through needle sharing and transmit the virus through high-risk 
sexual contact (12, 48).   
Mother-to-child transmission (MTCT) of HIV is a very common form of 
transmission in developing nations, where about 1,000 positive infants are born 
with HIV each day, but not in industrialized nations, where standards of care 
maintain HIV testing prior to childbirth and access to free antiretroviral treatment 
to prevent infection in infants (18, 133).  MTCT of HIV occurs primarily during 
childbirth, during which the infant is exposed to HIV-infected blood and during 
breastfeeding, during which the infant is exposed to HIV-infected milk.    
Social factors that bolster sexual HIV transmission globally include the 
sex trade, concurrent sexual relationships, and lack of gender equality (70).   
There are additional factors that significantly impact HIV transmission in sub-
Saharan Africa.  Wife sharing and inheritance, malaria, and TB are factors not 
shared by industrialized nations that contribute to the HIV epidemic in Africa (2, 
21, 76, 138).  Infection with malaria has been shown to increase HIV viral load by 
at least one order of magnitude and HIV infection increases susceptibility to 
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malaria (2). A positive correlation between viral load in blood plasma and viral 
load in genital secretions increases the likelihood that infection with malaria may 
increase the risk of sexual transmission of HIV-1 (72).  Further, dual infection has 
been shown to cause poor birth outcomes in pregnant women (8).   
HIV Biology. HIV is a retrovirus in the genus Lentiviridae. Retroviruses 
are characterized by reverse-information flow and integration into host 
chromosomes: immediately following infection, HIV-1 RNA is transcribed into 
viral DNA, which is transported to the nucleus and integrated into the host 
chromosome. Following integration, mRNA is transcribed from provirus to make 
precursor proteins that facilitate replication and cellular egress. Mature HIV 
virions are approximately 100 nm in size, contain two copies of positive-sense 
single stranded RNA, and are covered in glycoproteins that facilitate immune 
evasion.  The genome is approximately 10,000 bp in length and is protected by a 
nucleocapsid embedded inside a lipid bilayer (57). 
HIV infection causes chronic immune deficiency by infecting two 
essential immune cells, macrophages and T-helper lymphocytes. Infection with 
HIV-1 is mediated by the cellular surface receptor CD4, which is expressed on the 
surface of both cells.  CD4 plays a role in amplifying immune signaling 
associated with T-cell Receptor (TCR) and in detecting antigen by associating 
with Major Histocompatibility Complex (MHC) II (35, 68).  Initial infection with 
HIV occurs in macrophages and is mediated by the cellular co-receptor CCR5 
(115).  Evidence suggests that a single founder virus may be responsible for the 
subsequent proliferation of HIV throughout the body (37, 77). During the 
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asymptomatic period of infection, the tropism of HIV changes from macrophages 
to T-helper lymphocytes (69).  Infection of T-helper lymphocytes in blood is 
mediated by the cellular receptor and co-receptor CD4 and CXCR4, respectively 
(14).  
HIV surface proteins gp120 and gp41 mediate attachment to cellular CD4 
receptors.  Gp120 has been shown to mediate attachment, and gp41 mediates 
virion fusion (22, 38). Antibodies generated against HIV gp120 should block viral 
binding and attachment, however, because gp120 is highly glycosylated and 
changes regularly as a result of mutation, broadly neutralizing antibodies are very 
difficult to generate (141).  
HIV encodes several unique enzymes that facilitate replication, 
integration, and egress. Of particular interest is the viral polymerase, reverse 
transcriptase, which reverse-transcribes viral RNA into DNA following uncoating 
in a host cell.  Reverse transcriptase is an extremely low-fidelity polymerase, 
making about one error per 10,000 nucleotides transcribed, or one error per 
genome copy (90).  This very high rate of mutation is the basis for the global 
genetic diversity of HIV. Characteristic of lentiviruses, HIV also encodes an 
integrase enzyme that promotes integration of viral DNA into the host 
chromosome, creating a provirus. Also notable is an essential viral protease, 
which cleaves a precursor protein into functional enzymes, including reverse 
transcriptase and integrase.  This cleavage occurs following egress from a host 
cell and prior to attaching to a new target host cell (4).  
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HIV Disease Progression. Evidence indicates that sexual transmission 
of HIV-1 in the vagina usually begins with cell-free virus present in genital 
secretions. Langerhans cells that transverse the multilayered squamous epithelium 
are CD4 and CCR5 positive and therefore can be infected by HIV-1.  Epithelial 
Langerhans cells have projections that sometimes reach into the lumen of the 
vagina and represent targets for HIV binding and fusion. In addition, tears in the 
vagina expose submucosal CD4 positive T cells, macrophages, and dendritic cells 
(DCs) for viral access.  Two forms of sex popular in Africa, rough and dry sex, 
likely contribute to increased HIV infection among women through this 
mechanism. Once an epithelial Langerhans cell has been infected, it exposes 
submucosal macrophages, T-cells, and DCs to HIV-1.   
Within 7-14 days of exposure, evidence suggests that a small pool of 
submucosal HIV-1 infected CD4 positive T-cells travel to nearly gut-associated 
lymphoid tissue (GALT) and launch an infection from which HIV-1 is 
disseminated and viremia is established (26). GALT is the most significant 
reservoir of CD4 positive T-cells in the body(98). In newly infected individuals, 
HIV-1 RNA levels in GALT CD4 positive T-cells have been shown to be 10 
times higher than those found in the infected CD4 positive T-cells of the 
peripheral blood (99). HIV-1 causes rapid and severe T-cell destruction in GALT, 
depleting 50% of the CD4 positive T-cells in early infection. Even years of fully 
suppressive cART has not been shown to effect full recovery from this depletion 
(89).   
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When HIV infection initially occurs in a healthy person, high levels of 
viral replication occur in blood (121).  HIV-1 peak viremia during the first few 
weeks of infection is sometimes associated with relatively nonspecific symptoms, 
including fatigue, fever, lymphadenopathy, sore throat, rash, joint pain, myalgia, 
and diarrhea (25, 144).  This is known as ‘acute HIV syndrome’ and usually lasts 
not more than two weeks, followed by a sharp decrease in viral load, which 
occurs in part as a result of the immunologic activity of cytotoxic T-lymphocytes 
(13).  What follows this decline in virus replication is usually an extended period 
during which infected individuals are asymptomatic. This period is characterized 
by steady-state levels of virus in the bloodstream maintained by continuous viral 
replication and infection of new cells and turnover of infected lymphocytes in the 
blood (129).  The steady state level of the viral load during this period is known 
as the ‘set point’ and correlates with the rate of progression to AIDS (130).   
The immune system lags months behind in the development of 
antibodies and cytotoxic T-lymphocyte (CTL)-specific responses to HIV (92, 
117).  When a species of CTL or antibody is evolved that neutralizes the majority 
population of HIV, an HIV subpopulation featuring an escape mutation becomes 
dominant.  Evolution of a subsequent neutralizing response takes several weeks, 
during which HIV again replicates to high levels (56).  After many cycles, it is 
usual that viral fitness is compromised by the accumulation of escape mutations.  
However, HIV-1 infection and disease progression is not significantly adversely 
impacted by the accumulation of escape mutations.  Indeed it has been shown that 
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HIV-1 can revert escape mutations to improve viral fitness if the mutation is no 
longer needed (83).   
Viral load fluctuates around the set point according to health challenges 
faced by infected individuals. For example, co-incident infections with other 
pathogens has been shown to increase viral load (129).  This occurs as a result of 
the activation of T-cells with latent HIV infection. When such a T-cell is activated 
in response to a stressor, HIV replication increases in the cell and the cell is 
eventually destroyed as a result of viral replication. This results in increased 
depletion of T-cells.  
Other factors that impact patient health include nutrition, exercise, and 
sleep (32, 80, 106, 125). In the absence of treatment, the progression of HIV 
disease to AIDS takes an average of 8-10 years (101).  By this point, significant 
damage has been done to the immune system such that viral load begins to peak 
again and immune cell counts decline.  
Because CD4 positive cells are involved in coordinating immune 
responses, the absence of these cells indicates deterioration of immune health. In 
the absence of CD4 positive lymphocytes, the immune system becomes 
vulnerable to pathogens for which it would otherwise have an effective response.  
In untreated AIDS patients, death occurs as a result of complications associated 
with OIs and not usually as a direct consequence of HIV replication.  For this 
reason, CD4 counts are usually considered to be the best predictors of mortality. 
Another way to define AIDS is by the presence of an ‘AIDS-defining’ 
opportunistic infection (OI) coincident with HIV infection.  OIs vary by 
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geographical region, socioeconomic status, and genetic predisposition.  However, 
a few OIs are globally ubiquitous, including pneumonia caused by pneumocystis 
carinii. OIs require treatment distinct from cART. Indeed, if antiretrovirals are not 
effective, one indication may be the presence of an OI. However, OIs should not 
be used as diagnostic indicators for the efficacy of cART: by the time an OI can 
be diagnosed, it may be too late for the patient to reach a treatment center, 
particularly in developing countries, where significant barriers keep patients from 
accessing health services.  Additionally, there is a lack of treatment for some OIs 
such that the best course of therapy is to utilize cART to support immune 
reconstitution (65). 
  Antiretroviral Drug Targets. Because eukaryotic cells do not natively 
make reverse transcriptase, protease, and integrase, they serve as excellent targets 
for drug development.  Some of the drugs first developed to treat HIV infection 
were nucleoside analog reverse transcriptase inhibitors (NRTIs) and protease 
inhibitors (PIs). As of 2010, the US FDA approved the use of 33 different ARVs 
in 6 classes for HIV treatment.  Significant side effects make it difficult to adhere 
to all antiretroviral drugs, particularly where medicines are not widely available to 
ameliorate adverse reactions. 
NRTIs take advantage of the high susceptibility of reverse transcriptase to 
substrate analogs. NRTIs are malformed nucleosides that terminate chain 
synthesis when incorporated into a growing DNA strand.  Because not all cellular 
polymerases are perfectly substrate-selective, serious side-effects occur as a 
consequence of taking NRTIs, including peripheral neuropathy, myopathy, and 
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lactic acidosis (71). Further, there is evidence that protease inhibitors also inhibit 
cellular proteases and are in part responsible for the lipodystrophy experienced by 
some patients (20).  The toxicities associated with these drugs can make 
adherence difficult for people who lack access to medical services and treatments 
that ameliorate side effects associated with antiretroviral drugs.  
HIV Drug Treatment and Adherence. While drug treatment with NRTIs 
or PIs have been shown to be effective against HIV enzymes, used alone, either 
will produce a temporary improvement in viral load that lasts for a few weeks 
followed by a rapid return to pre-treatment levels. This can be accounted for by 
the activity of reverse transcriptase.  Several antiretroviral drugs can be rendered 
ineffective through a single nucleotide change made by reverse transcriptase; the 
accumulation of errors facilitates mutant escape from any individual drug (29).  
Consequently, ARVs are administered in multi-drug cocktails known as 
combination anti-retroviral therapy (cART), which are highly effective in 
suppressing viral replication and halting disease progression.  
Precise adherence to cART has been shown to reduce viral load to 
undetectable levels over long periods of time (more than 20 years).  Because 
mutation occurs only as a result of viral replication, the profound suppression of 
replication effected by adherence to cART significantly reduces the evolution of 
drug-resistant virus (HIVDR).  However, it has been shown that sub-optimal (less 
than 90%) adherence to some cART drugs (PIs in particular), creates excellent 
conditions for the evolution of HIVDR (111).  Therefore, it is critical that 
individuals participating in cART treatment programs strictly adhere to drug 
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schedules and for clinicians to regularly assess viral load to determine drug 
efficacy (27, 104, 111, 114). It is especially important to measure viral 
suppression early in cART treatment, since it has been shown that patients who 
experience complete suppression in the initial stages of treatment are more likely 
to maintain complete suppression even if adherence drops off with time to less 
than 75% (118). 
The Threat of HIVDR in sub-Saharan Africa. Increased humanitarian 
aid to Africa has resulted in the implementation of large-scale public health 
programs for HIV and the scaling up of distribution for cART. As of 2010, the 
largest program for provision of free antiretroviral drugs in sub-Saharan Africa is 
providing cART for more than 3.2 million people (67).  This program, the U.S. 
President’s Emergency Plan for AIDS Relief (PEPFAR) has increased the number 
of participants receiving free cART by 100% on average per year over the last six 
years and plans to continue coverage increases (67).  
In developing countries, the patient costs associated with treatment, stigma 
associated with HIV infection, and structural impediments to provision of the 
drugs increase barriers to adherence (100). The widespread availability of cART 
drugs, in conjunction with these barriers to adherence, increases the likelihood of 
HIVDR evolution in developing countries. It is estimated that at least 5%-20% of 
patients will fail first-line therapy within their first four years of therapy despite 
adequate adherence and effective blood plasma drug levels (19, 75). Indeed, it has 
been shown in randomized comparisons between drug regimens common in 
developing countries that resistance mutations accumulate despite optimal 
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adherence (10).  Because there are limited drug classes for global use, HIVDR 
threatens to obsolete treatments available in developing countries and eventually 
in industrialized nations (11, 111).  Moreover, viral genotyping tests are more 
costly and more complex than viral load testing. As a result, it is unlikely that 
effective and broad surveillance for HIV drug resistance can be implemented in 
sub-Saharan Africa.  
HIV Testing. The genetic diversity of HIV creates significant challenges 
for both protein and nucleic acid-based diagnostic testing (63, 132). Protein 
structural changes and post-translational modifications have stymied the 
development of a single protein-based test for HIV. For example, public health 
sero-status tests for HIV have not consistently detected HIV-1 group O infection 
or HIV-2 (60).  
Diagnostics for HIV based on nucleic acids offer clinical advantages over 
those based on proteins.  For example, HIV RNA viral load has been shown to 
correlate very well with progression to AIDS, while p24 protein tests have not 
been shown to consistently correlate well with disease progression (16, 113, 116, 
131).  In addition, even the best protein tests are less sensitive than RNA-based 
detection of HIV-1 (86, 110).  As a consequence of these problems, there is 
increased focus on nucleic acid test development for the genetic populations of 
HIV that represent the large majority of global HIV infection.   
Clinical diagnostics for HIV fall into two categories. Sero-status tests 
indicate whether or not a person has sero-converted in response to HIV. Health 
management tests provide clinical information about patient health and disease 
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progression. HIV sero-status tests include the enzyme-linked immunosorbant 
assay (ELISA) and Western Blot.  There are three health-management tests for 
PLWHA: the CD4 count, viral load test, and viral genotyping. The CD4 count 
measures the number of CD4 positive lymphocytes in a cubic millimeter of blood 
and directly correlates to immune health.  The HIV viral load test measures the 
HIV RNA copy number per cubic millimeter in the blood and inversely correlates 
to immune health.  HIV-1 genotyping tests determine viral drug resistance 
through an analysis of the nucleic acid sequence of dominant HIV quasispecies.  
The ELISA test is used internationally to screen for HIV infection. The 
test is inexpensive, does not require cold chain, skilled labor, or power, and has a 
tiny footprint. ELISA tests do not directly detect the presence of HIV. The 
presence of antibodies to HIV is instead used as a surrogate market for infection.  
In addition, ELISA HIV tests have a relatively high rate of false-positive results. 
Industrialized nations have the resources to perform Western Blot confirmatory 
testing to ensure that positive results are a true positive results.   
While the Western Blot can be used to evaluate sero-status with higher 
accuracy than the ELISA test, it is expensive, requires highly skilled labor, 
specialized equipment, and a stable power source.  Moreover, the Western Blot 
also uses the presence of antibodies to HIV as a surrogate marker for diagnosing 
infection.  Because the resources required to perform Western Blot testing are 
significant, the test is largely not performed in developing countries.  Instead, the 
protocol for confirmation calls for two ELISA tests from different manufacturers.  
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The weakness inherent in this testing protocol for developing countries 
is exacerbated by population-wide testing efforts. It is anticipated that the high 
rate of false positive test results associated with the ELISA in combination with 
large numbers of people seeking testing will create the conditions for people to 
receive false positive test results.  Because Western Blot and viral load tests are 
performed rarely for PLWHA in sub-Saharan Africa, some people given positive 
results may never realize that they are HIV negative.  For this reason, there is a 
need to change the HIV sero-status testing protocol for developing nations, either 
through the addition of resources to meet the standard of industrialized nations or 
through the development of new technology to provide more accurate sero-status 
test results. 
Health management for PLWHA necessitates CD4 count and viral load 
testing, which provide clinicians with information about the health of the immune 
system and the rate of progression to AIDS, respectively. The CD4 count is an 
essential clinical point-of-care diagnostic, such that the primary basis for the 
definition of AIDS is infection with HIV and a CD4 count less than 200 cells per 
cubic milliliter of blood.  CD4 counts rely on flow cytometry assays, which 
require expensive equipment, skilled labor, uninterrupted power, and reagents that 
require a cold chain supply system.  As a result, CD4 count testing is available 
largely in regional centers in sub-Saharan Africa and not in rural areas.  
The most direct method to detect the presence of HIV is to test blood for 
viral RNA.  This test is known as a “viral load” test, because it measures the 
amount of HIV, or ‘load’, by measuring the number of copies of HIV present in 
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blood. The conventional viral load assay is an FDA approved test for clinical 
evaluation and monitoring of the number of copies of HIV viral RNA per cubic 
millimeter of blood. The assay is based on real-time polymerase chain reaction 
(RT-PCR) and thus requires a thermal cycler with a laser and fluorescence 
detection capability.  RT-PCR relies on DNA primers, nucleotide triphosphates, 
buffers, and enzymes that require cold storage at either 4 C or -20 C.  In addition, 
conventional viral load assays require computers with analysis software sufficient 
to provide diagnosis based on the data generated by reactions.   
There are three companies currently producing FDA-approved HIV-1 viral 
load assays: Roche, Siemens, and bioMerieux.  While the assays produced by all 
companies are nucleic acid tests, each assay utilizes a different approach to detect 
the presence of HIV-1 RNA.  While Roche and bioMerieux base their approaches 
on target amplification, Siemens’ assay utilizes signal amplification to achieve 
highly sensitive results.  All of the assays are quantitative, highly sensitive, and 
support broad ranges of RNA input.   
The extraordinary level of detail and complexity of performing 
conventional viral load testing is particularly prominent when human resources, 
operations, parts, supplies, and support are taken into account. Concerned about 
quality, the government of Tanzania actually created a national guideline in order 
to harmonize the purchase, operations, and support of viral load equipment in the 
country (93).  Moreover, conventional viral load is so complicated that, when 
comparison tested, several US FDA-approved assays were shown to produce 
clinically significant viremia differences (66).   
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HIV Viral Load and Patient Outcomes. In the absence of viral load 
testing, the World Health Organization (WHO) released guidelines for evaluating 
efficacy of cART utilizing CD4 counts and clinical criteria for developing nations 
(52). This policy leverages the presence of urban and regional CD4 count tests 
already used to determine appropriate commencement for cART. However, the 
CD4 count assay has been shown to be a poor predictor of virologic failure in 
HIV infected individuals receiving cART (97, 120, 131).  
In a study of clinicians in developing countries, those without access to 
viral load testing waited over 5 months longer on average to switch failing 
patients to second line therapy compared with clinicians who had access to viral 
load testing.  Further, patients treated by clinicians who did not have access to 
viral load testing experienced a 40% greater decline in CD4 count compared to 
patients treated by clinicians who had access to viral load testing (78). Viral load 
testing is an important component of health management for PLWHA in 
developing countries: clinicians cannot effectively intervene when drugs are 
failing without viral load monitoring.   
It is now estimated that clinical and immunological monitoring 
misclassifies almost one-half of patients with virologic failure (120). Individuals 
pay for this mistake with their health, programs pay for it with increased costs, 
and communities pay for it with the increased likelihood of HIV resistance to first 
and second-line drugs.  The problem is severe enough that managing cART 
without viral load monitoring has been referred to as “running with scissors” 
(127). 
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Conventional viral load testing is cost-prohibitive for large-scale 
surveillance of HIVDR. Indeed, PEPFAR has no monitoring in place for HIVDR 
in many of the countries to which it provides the large majority of its free public 
cART, including Tanzania, South Africa, Kenya, Nigeria, and Zambia (67). There 
is a critical need for monitoring because no third-line regimens are available 
through public health programs and fewer classes of drug are available in 
developing countries (120). Thus a widespread outbreak of HIVDR would likely 
cause a health crisis for people living in sub-Saharan Africa (78). 
HIV Viral Load and Prevention of Mother-to-Child Transmission. 
Almost one-thousand babies have been born with HIV in sub-Saharan Africa 
through MTCT each day since 2003 (134, 135). Improvements in ARV 
availability have reduced MTCT of HIV such that 114,000 infant infections were 
averted through PEPFAR in 2010 (67).  Because HIV MTCT is highly correlated 
to viral load, without knowing a mother’s viral load, it is difficult to assess the 
risk of transmission to her infant.  Furthermore, sero-status tests for HIV detect 
antibodies to HIV as a surrogate rather than detecting HIV directly.  Because 
infants carry their mothers’ antibodies for 18 months after birth, it is impossible to 
know if a child is HIV positive during that time without a viral load test.  While 
cART is very effective in preventing HIV replication, it is toxic and should not be 
prescribed to healthy babies (49).  Clinicians who do not have access to viral load 
testing may be required to prescribe 18 months of cART for infants exposed to 
HIV irrespective of whether the exposed infant is HIV infected.   
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 Inexpensive Viral Load as a Confirmatory HIV-1 Screen. HIV Viral 
sero-status tests for HIV are based on ELISA technology. The HIV ELISA test is 
inexpensive, durable, has a low rate of false-negative results, and provides 
consistent results throughout years of HIV diseases progression.  However, HIV 
ELISA tests have a relatively high rate of false-positive results. Clinicians in 
developing countries therefore use a second HIV ELISA test (usually produced by 
a different manufacturer) to confirm HIV positive results.  This protocol is 
dictated by the resources available to clinicians in developing countries. 
Clinicians in industrialized countries use confirmatory HIV tests, including the 
Western Blot and viral load test to ensure true positive results. If the viral load test 
could be reduced in cost, it could be used as an accurate and effective 
confirmatory test for developing countries. 
Mixed-Method Approach to Development and Testing.  Inexpensive 
viral load testing is currently the focus of international attention and effort.  
Through reductions in kit price and the development of alternative technologies, 
researchers and policymakers are working toward a widely available viral load 
test for sub-Saharan Africa.  However, relatively little research has assessed 
whether regional or rural providers want or understand viral load testing.   A 
mixed-method approach was undertaken to better understand the needs and 
requirements of PLWHA in sub-Saharan Africa and their medical providers. 
 Technology transfer and capacity-building are key efforts in the campaign 
to reduce HIV infections globally.   Medical technology developed for use in low-
income countries must address problems specific to resource-limited settings and 
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must be based on engineering parameters that fulfill appropriate use 
specifications.  However, simply developing technology for developing countries 
is not enough. New technology must be adaptable to user culture, address local 
priorities, fulfill training needs, and meet supply chain requirements. 
 These elements have not been sufficiently appreciated in regard to health 
technology in sub-Saharan Africa.  In 1994, the World Health Organization 
stated, “Efforts to strengthen national information systems have often produced 
little improvement and have sometimes made the problem worse” (1). Without an 
understanding of local structures and organizational forces, it is very difficult to 
know how a new technology will be perceived and adopted.  
 In a case study entitled, “Rejection of an innovation: health information 
management training materials in east Africa,” a large technology transfer project 
failed and innovations were rejected due to a difference in perception between 
implementers and users (54).  In particular, local users perceived a technological 
change to be an organizational change and resisted adoption. Project leaders failed 
to understand organizational structures and forces and therefore could not respond 
to adjust aspects of their innovation that were not fitting well with the 
organization. 
 Technological innovation intended for use in sub-Saharan African cannot 
end with production of a working device.  Production is the last step of research 
and development and the first step of an entirely new process of implementation 
that must be locale-specific. Lessons learned in the field suggest that technology 
transfer teams must learn local approaches, policies, and organizational, 
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management, and presentational styles in order to reflect them during the 
technology transfer process (53).    
 Culture informs every aspect of life in sub-Saharan Africa, including and 
perhaps especially, healthcare. The incorporation of social science approaches 
into needs assessments for medical technology in developing countries may 
deliver significant benefits over current methods.  Medical science researchers 
trained to evaluate needs based on engineering parameters may miss pivotal 
cultural information that would inform a successful technological development 
and adoption project.  
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Chapter 1 
THE DEVELOPMENT OF A NOVEL, LOW-COST DIAGNOSTIC FOR HIV-1 
INTRODUCTION  
Attention to the enormous burden of HIV-1 in developing countries has 
brought resources to Africa from industrialized nations for prevention and 
treatment of HIV and AIDS.  One of the most important aspects of foreign aid is 
the scale-up of antiretroviral therapy for Africa.  As of 2011, 3.2 million Africans 
are receiving antiretroviral treatment for HIV through the US program PEPFAR.   
 While PLWHA in industrialized nations receive cART and adequate 
health monitoring, people infected with HIV in Africa receive inadequate health 
monitoring.  In addition to infrequent CD4 counts, viral load monitoring is largely 
absent. It has been argued that scaling up cART availability in Africa requires a 
simplified approach (19). Indeed, WHO guidelines for evaluating virologic failure 
call for CD4 counts and clinical assessment in the absence of viral load testing.  
Focus on conventional viral load testing has led some to identify 
inadequate laboratory capacity as the reason for poor coverage of viral load 
testing (19).  However, in some ways, this perspective places undue emphasis on 
the system of medicine used by industrialized nations for treatment of PLWHA.  
Further, it fails to acknowledge that conventional viral load testing was developed 
by US and European institutions largely for use in those countries according to 
the style of care commonly employed there.   
The healthcare structure in much of Africa is different from that which 
exists in industrialized nations.  With regard to HIV in particular, mobile 
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voluntary testing and counseling (VCT), community health worker networks, 
regular home healthcare visits, and rural health centers, staples of African models 
of HIV care, are almost completely absent in industrialized models for healthcare.    
While much of the international discussion on viral load testing for Africa 
is focused on reducing kit cost and building capacity to install conventional viral 
load equipment in regional centers (following the course of action taken with CD4 
testing), shifting the focus to the development and validation of technologies that 
are suitable for healthcare models employed by developing nations for HIV 
treatment may be more effective. A more comprehensive and targeted approach to 
healthcare for PLWHA in sub-Saharan Africa includes capacity-building for 
regional conventional viral load testing in addition to the distribution of validated 
medical technology for use at the point of care in rural settings. 
Conventional HIV viral load testing is based on polymerase chain reaction 
(PCR).  The relatively high cost associated with viral load testing can largely be 
attributed to the need for a thermal cycler equipped with fluorescence detection 
connected to a computer equipped with the software required to analyze results. If 
an alternative amplification assay could produce as much product as PCR and 
occur under isothermal conditions (eliminating the need for a thermal cycler and 
computer), the cost associated with viral load could be tremendously reduced.  
As of November 2010, there are three FDA-approved HIV-1 viral load 
tests: the Roche Amplicor Monitor and COBAS Amplicor (Roche), NucliSENS 
HIV-1 QT (bioMérieux), and the Versant HIV-1 RNA assay (Siemens) (45).  The 
Roche Amplicor assay is a target-amplification RT-PCR based assay which 
  25 
targets HIV gag p24.   The NucliSENS HIV-1 QT assay is based on nucleic acid 
sequence based amplification (NASBA), an isothermal target amplification 
method that utilizes a T7 RNA polymerase to create a feedback cycle of reverse 
transcription and amplification that significantly increases reaction yield.  The 
Versant HIV-1 RNA assay is a signal amplification assay utilizing branched DNA 
(bDNA).   
Comparisons between assays based on kit prices have been widely used to 
discuss the cost of viral load testing.  However, the differential capital investment 
required for disposables, skilled technicians, assay duration, and lab space 
requirements have led researchers to develop a cost model to incorporate these 
factors (41). The price per test varies between $50-$139 USD depending on the 
assay and whether the sample is part of a high- or low-throughput run.  
However, even these assessments fail to incorporate capitalization 
required for equipment. It is more difficult to incorporate this cost because of 
variations in the number of low- and high-throughput test runs performed per year 
with each assay base. Some of the equipment required for conventional viral load 
testing are priced at over $50,000 USD.  When this cost is incorporated to test 
prices, it is hard to imagine that the true cost of per-test viral load monitoring 
would not increase by at least 5-10 dollars per test run. 
Alternative Viral Load Technologies. If the cost and resource 
complexity associated with the conventional viral load test could be decreased, 
large-scale advances could be made in HIVDR surveillance, and for patient 
outcomes, infant diagnosis, and in screening for HIV sero-status (19). Simple and 
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inexpensive point-of-care HIV-1 viral load diagnostic testing for the increasing 
number of HIV-positive individuals participating in treatment programs is now a 
crucial issue for sub-Saharan Africa (46, 62, 122, 137).   
 Consequently, several alternative technologies have been proposed to 
replace conventional viral load testing. However, even alternative technologies 
face adoption challenges, either because of the requirement for skilled 
technicians, a capital intensive set-up, or because science supporting clinical use 
has not been established (46, 58, 120). Assays under consideration for use in 
developing countries have been summarized in Table 1 in conjunction with their 
respective disadvantages and limitations.   
 Dried blood spot (DBS) technologies show great promise in facilitating the 
collection of samples from rural areas without reducing the accuracy of testing 
(85). The use of DBS technology is based on a transport approach for viral load 
testing: blood collected in rural areas is shipped to central conventional viral load 
testing facilities.  In order for this approach to be successful, regional centers must 
have viral load testing capability.  
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# Assay  Type Advantages Disadvantages 
1 bioMérieux 
NucliSENS 
HIV-1 QT 
Nucleic acid, 
NASBA 
Can be used with dried 
blood spots, effective 
for clades A-D, can be 
used with all 
biological fluids. 
High cost ($40-100 USD), 
postamplification steps 
required, dedicated space 
and equipment, high 
technical skill, technical 
support required. 
2 Siemens 
Versant HIV-1 
Quantiplex 
Nucleic acid, 
bDNA 
(detecting 
HIV-1 RNA) 
High-throughput, can 
be fully automated, no 
separate extraction or 
amplification areas in 
the lab need to be set 
up. 
High cost ($125 USD), 
dedicated space and 
equipment, 22 hour waiting 
period for results, high-
med technical skill, 
technical support required.  
3 PerkinElmer 
Ultrasensitive 
p24 
p24 Antigen Training available at 
CDC, Rush, and 
through manufacturer, 
equipment shared with 
ELISA, high 
throughput, 0.05 mL 
plasma input sample. 
Requires more clinical 
evaluation, need to 
understand the clinical 
impact of non-virion 
associated p24, 3-5 hour 
waiting period for results, 
requires further evaluation 
in a variety of sub-types, 
high technical skill. 
4 Cavidi ExaVir Reverse 
Transcriptase 
Activity 
Easy training available 
through manufacturer, 
simple assay, 
inexpensive 
equipment, can be 
used for NNRTI 
resistance assays.    
Requires more clinical 
evaluation, dedicated 
incubator and vacuum 
pump, 1 mL of plasma as 
input, 3-day waiting period 
for results, further 
evaluation in a variety of 
subtypes.   
5 Abbott 
Realtime  
HIV-1 
RT-PCR High-throughput, large 
dynamic range. 
Very expensive equipment, 
dedicated equipment and 
space, requires more 
extensive evaluation in 
non-B subtypes, need good 
technical support. 
6 HIV-1 LAMP Nucleic acid, 
DNA or RNA 
Low cost, results in 
less than 2 hours,  
simple process, results 
read by the unaided 
eye.  
Non quantitative, requires 
further validation for non-b 
subtypes, still a research 
assay,  no corporate 
backing for FDA 
approvals. 
 
Table 1. Viral load assays under consideration for use in developing countries.  
Adapted from the PerkinElmer p24 ultrasensitive assay protocol, Fiscus et al. 
(2006) and Stevens et Al. (2010) (46, 131).  
 
 A large number of parameters need to be satisfied simultaneously in order to 
make low-resource HIV-1 viral load testing a reality. International focus has been 
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on building capacity to incorporate conventional testing and on reducing reagent 
and kit costs.  Reagent and kit cost must be minimized because PLWHA in 
developing countries cannot pay for expensive tests and public health programs 
cannot afford to pay high per-unit prices for universal testing. However, reagent 
costs are only the beginning of the parameters that must be addressed. 
 Capital investment must be minimized because developing countries lack 
the finances necessary to buy equipment.  Equipment powered by AC should be 
replaced with battery power if the assay is to be used in rural settings.  The 
equipment footprint should be small so that regional and rural laboratories have 
space to accommodate the assay.  The assay should be simple and involve few 
steps so that unskilled technicians can produce accurate results.  Reagents must 
not require a cold chain, and be shelf, temperature (up to 40 ˚C), and somewhat 
moisture stable in order to be used in rural areas and varying climates.  Finally, 
the assay should produce rapid and accurate results in less than 2 hours so that 
PLWHA can receive test results during the same appointment.  
 The failure of viral load in developing countries led Médecins Sans 
Frontières to conduct a survey of medical providers in Brazil.  The survey 
gathered information about appropriate characteristics for a viral load test that 
could be used in resource-limited settings (91).  One interesting aspect of the 
responses is that clinicians were not interested in highly quantitative viral load 
results.  Instead, they asked for a semi-quantitative assay that could detect 
treatment failure with a threshold value of 10,000 copies of virus per mm3 (91). 
Considering this new information and the complexity associated with satisfying 
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all of the parameters associated with quantitative HIV-1 viral load 
simultaneously, a new approach utilizing a semi-quantitative assay with a range of 
threshold values or a rough estimate above or below 10,000 copies of HIV-1 RNA 
per mm3 may yield benefits (119). 
 An innovative approach that has not been widely discussed is to use a tiered 
system for viral load assays featuring a qualitative rural point of care viral load 
assay to screen for virologic failure and a quantitative assay at the regional level 
to assess more accurately the need for second-line therapy.  This would reduce the 
number of constraints on a quantitative assay since many regional centers already 
feature CD4 count testing supported by uninterrupted power, cold chain capacity, 
skilled labor, and lab space for CD4 count assays.  Capitalizing on clinicians’ 
observation that highly quantitative and sensitive viral load monitoring is not 
necessary, a viral load screening assay could be developed that would meet most 
needs.  Indeed, eliminating the need for rural quantification quickly reduces the 
number of constraints that must be met in order for a viral load assay to be used in 
low-resource settings.   
 One technology that lends itself to this application was described by Notomi 
et al. in 2000 and referred to as loop-mediated isothermal amplification (LAMP) 
(107).  The technology is characterized by a target-based isothermal amplification 
that rapidly produces quantities of product that can be observed by the unaided 
eye (55).  Because the amplification is isothermal and product can be visualized 
by means of colorimetric or fluorescent indicators, the requirement for expensive 
equipment is eliminated. The thermal cycler, fluorescence detection, computer, 
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and analysis software required by conventional viral load nucleic acid assay 
approaches are not needed for LAMP.    LAMP reactions utilize more primers 
than typical PCR: 6 primers that bind 8 specific and distinct sequences within the 
target.  Primers are designed such that reaction intermediate stem-loop structures 
are produced that self-prime to increase reaction output (Figure 1).  
 A growing body of research has validated LAMP technology for the 
detection of infectious agents in humans and animals in both industrialized and 
developing nations (15, 81, 140, 142, 143, 145-147).  A modified reverse-
transcriptase (RT) LAMP assay has also been described to detect HIV-1 RNA 
(33).  This study demonstrates that RT-LAMP can be used to detect HIV-1 clade 
B utilizing a fluorescent indicator and the unaided eye. 
 While the LAMP assay is promising as a potential point of care diagnostic 
technology for low-resource and rural settings, further development is required.  
First, sample preparation remains a problem (39). The published consensus 
prerequisite for highly sensitive LAMP is purified viral nucleic acid.  Thus, 
samples must undergo whole blood lysis followed by DNA/RNA extraction and 
purification.  These operations require several technical steps that include the use 
of a centrifuge.  As a result, skilled labor and uninterrupted AC power continue to 
be a requisite for LAMP.  Second, because LAMP has been suggested for use in 
developing countries, an assay designed to detect HIV-1 clade C virus is 
necessary. 
 Here we present an alternative approach to sample preparation and the 
successful detection of HIV-1 clade C RNA in whole blood using RT-LAMP.  
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Figure 1. RT-LAMP reaction theory. Step 1 and Step 2, after the binding of 
the forward inner primer (FIP), comprising the F2 and F1c sequence, 
reverse transcriptase extends a new DNA chain.  Step 3, the forward outer 
primer binds and polymerase strand displacement activity separates the 
DNA-RNA hybrid. Step 4, Step 5, and Step 6, the product from Step 3 is a 
double-stranded and single-stranded molecule, focusing on the strand that 
has been released by displacement, the backward inner primer (BIP) binds 
and polymerase extends a new DNA chain.  Step 7, the backward outer 
primer binds and polymerase separates the dsDNA chain while elongating 
a new DNA chain. Step 8, focusing on the strand released in Step 7, the B1 
sequence anneals to a B1c internal complementary region and F1 anneals 
to an internal F1c region.  The F1:F1c hybridization region can serve as an 
internal primer. Adapted from Notomi et al. (107). 
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MATERIALS AND METHODS 
 Blood samples. Blood samples were obtained from Blood Systems, 
Phoenix AZ.  Blood samples ASU10-01 through ASU10-21 were specimens left 
over from the diagnostic laboratory and were unlinked from personal identifiers 
before use. 
 In Vitro Transcription.  Plasmid p93IN999, a near full-length non-
infectious molecular clone of HIV-1 group M clade C was obtained from the NIH 
AIDS Research and Reference Reagent Program. p93IN999 is a clone of an 
Indian HIV-1 isolate that lacks 74 bp in the LTR R-U5 region and is in a pCR2.1 
background.   
 In vitro transcription was performed using a MaxiScript T7 In Vitro 
Transcription Kit (Applied Biosystems, Inc.) per the manufacturer’s specification. 
Briefly, p93IN999 was linearized by digestion with HindIII (New England 
Biolabs) for one hour at 37 ˚C.  In vitro transcription used 1 µg of plasmid 
template, 10 mM deoxyribonucleotides (DNTPs), 2 µL T7 polymerase, and 2 µL 
of room-temperature reaction buffer. Reactions were performed at room 
temperature for one hour in a final volume of 25 µL.  Reaction product was 
digested at 37 ˚C with DNase I to eliminate residual template and cleaned using 
an RNEasy Mini Kit (Qiagen) according to the manufacturer’s specification.  
 Reaction product was quantified utilizing a Nanodrop 1000 
spectrophotometer (NanoDrop Technologies, Inc.).  RNA absorbance peaks at 
260 nm indicated that the concentration of the transcribed RNA was 56.4 ng/µL 
and optical density (OD) 260/280 ratio measurements averaging 2.19 indicated 
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purity of product.  HIV-1 viral RNA copy number was calculated based on 
sample concentration, the molecular weight of ssRNA, and the length of the 
transcript produced through in vitro transcription of the plasmid (approximately 
9000 bp).  10-fold serial dilutions were performed to create a copy number range 
between 108 and 101 copies. 
 RT-LAMP Primer Design. Primers were designed for a gag consensus 
sequence specific to HIV-1 group M, clade C.  Briefly, over 500 clade C gag 
sequences were gathered from the Los Alamos National Laboratory HIV 
Sequence Database (www.hiv.lanl.gov) and aligned using BioEdit 
(www.mbio.ncsu.edu/bioedit/bioedit.html). A representative of conserved gag 
sequences was found in the subtype C isolate C.Br.92.BR025.d (Accession 
number U52953).   
 There are four requisite LAMP primers designed to hybridize with six 
conserved sequences within the target, termed F3, F2, F1, B3, B2, and B1.  The 
forward outer (F3) and backward outer primer (B3), are matches for the F3 and 
B3 sequences, respectively.  The forward inner primer (FIP) contains two 
hybridization domains, one that binds to the complement of F2, and one that binds 
the F1 sequence. The backward inner primer (BIP) contains two hybridization 
domains, one that binds to the complement of B2, and one that binds the B1 
sequence. Two additional primers, LoopF and LoopB bind to intermediate 
reaction products and are added to increase total reaction output. Sequences for 
LAMP primers are documented in Table 1.  LAMP primers bind HIV-1 subtype C 
in a conserved region of the gag gene, creating a 209 nucleotide product. 
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Primer 
Designation Sequence (5' to 3') 
F3 TGGGTAAAGGTAGTAGAGGAG 
B3 TTTGCTCATTGCCTCAGCCA 
FIP ATTTGCATGGCTGCTTGGTGT 
BIP CCAGTAGGAGACATCTATAAA 
LoopF CCCCTACTGTATTTAACATGG 
LoopB TAAATAAAATAGTAAGAATGTA 
(Amplified) 
Target 
Sequence 
(209 bp) 
ACACCAAGCAGCCATGCAAATGTTAAAAGATACCATCA 
ATGAGGAGGCTGCAGAATGGGATAGATTACATCCAGTG 
CATGCAGGGCCTGTCGCACCAGGCCAAATGAGAGAACC 
AAGGGGAAGTGACATAGCAGGAACTACCAGTACCCTTC 
AGGAACAAATAACATGGATGACAAATAACCCACCTGTC 
CCAGTAGGAGACATCTATAAA 
 
Table 2. RT-LAMP Primer Design. Primers were designed for a consensus 
HIV-1 subtype C isolate gag sequence. The anticipated amplification 
sequence is identified as a 209 nucleotide fragment of the gag gene. 
 
  
 Sample Preparation. DNA-based LAMP was carried out utilizing varying 
concentrations of linearized p93IN999 plasmid.  Plasmid was linearized by 
incubation with HindIII for one hour at 37 ˚C.  Following linearization, DNA was 
purified utilizing a DNeasy kit (Qiagen) according to the manufacturer’s 
specification.  Product DNA was diluted into the following concentrations: 25 ng 
(L), 50 ng (M), and 100 ng (H).  One microliter from each tube was used as 
template for a DNA LAMP reaction (Figure 2). 
 For RT-LAMP, whole blood was spiked with known concentrations of 
HIV-1 RNA and mixed briefly by pipetting.  Samples were then lysed using filter 
sterilized whole blood lysis solution comprising 2.5mM KHCO3, 37.5mM NH4Cl, 
and 0.025mM EDTA.  750 µL of lysis solution was added to 250 µL of blood 
spiked with HIV-1 RNA.  Samples were inverted for 15 minutes at room 
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temperature and centrifuged at 2,500 x g. The pellet was discarded and the 
supernatant containing nucleic acids was retained for sample processing.  
 Hemoglobin was selectively eliminated from the supernatant with the 
addition of Hemoglobind (Biotech Support Group) through a process described by 
the manufacturer.  Briefly, 250 µL of lysed blood is added to two volumes of 
Hemoglobind, vortexed for 30 seconds, and mixed by inversion for 15 minutes. 
The mixture is then centrifuged at room temperature for 2 minutes at 8600 x g. 
The supernatant is transferred to a new tube and was used for RT-LAMP. 
 It should be noted that some blood samples were processed separately by 
heat-treatment at 95 ˚C for 5 or 10 minutes respectively to test LAMP HIV-1 
detection (data not shown).  This approach did not produce any successful LAMP 
reactions.   
 Optimization of RT-LAMP Reaction Conditions. Optimization of the 
RT-LAMP reaction was performed by varying temperature (45-62 ˚C), betaine 
concentration (0.2-1.0 M), MgSO4 (1-8 mM), and primer concentrations.  Target 
RNA was added to the reaction in 10-fold serial dilutions and the amplification 
was performed for 60-80 minutes.  The most significant increases in sensitivity of 
the assay occurred as the result of increasing AMV reverse transcriptase (RT) 
concentration, increasing the volume of added template (i.e., adding the same 
number of copies in a greater volume), and adjusting primer concentration. 
Specifically, increasing AMV RT to 2 U per reaction and template input volume 
to 10 µL per reaction increased sensitivity by four orders of magnitude.   
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 RT-LAMP Amplification. The RT-LAMP reaction was carried out in a 25 
µL total reaction volume.  Each reaction contained 0.2 µM of each F3 and B3 
primers, 1.6 µM of each FIP and BIP primers, and 0.8 µM of each LoopF and 
LoopB primers, 0.8 M betaine (Sigma-Aldrich), 2 mM MgSO4, 1.4 mM DNTPs, 
1x Thermopol reaction buffer (New England Biolabs), 8 U Bst DNA polymerase 
(New England Biolabs), 2 U AMV reverse transcriptase (Invitrogen), 1x SYBR 
Green I (Invitrogen), and 8 µL of lysed whole blood with template.  Amplification 
was carried out using a water bath or an S-1000 thermal cycler (Bio-Rad) at 60 ˚C 
for 60 minutes, followed by incubation at 80 ˚C for 2 minutes.   
 Detection. Successful RT-LAMP reactions were characterized by 
fluorescence of the SYBR Green I fluor detected by the unaided eye. SYBR 
Green I peak fluorescence occurs when bound to DNA as compared to RNA. 
Successful reactions products were verified by agarose gel eletrophoresis.  
 Reaction success was also coincidently observed by real-time fluorescence 
measurement. Real-time reactions were prepared exactly as other RT-LAMP 
reactions. Reactions were performed under isothermal conditions in a Mini-
Opticon Real-Time PCR thermal cycler (Bio-Rad).  A SYBR Green I Filter was 
used to measure reaction success.  Opticon cycles, designed to change 
temperature, must be configured to cycle at the same temperature repeatedly. 
 Hydroxy-Napthol Blue (HNB) was utilized as an alternative detection 
approach as previously described (55).  Briefly, HNB was dissolved in nanopure 
water at 20 mM to prepare a stock solution.  All reaction constituents were held 
constant except that 120 µM HNB was added to the reaction master mix.  
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 RT-LAMP Specificity. Based on the consensus sequence, there is a PstI 
restriction digest site at nucleotide 52 in the reaction product. Specificity of RT-
LAMP was confirmed by PstI restriction digestion of LAMP concatemers.  The 
restriction digests were incubated at 37 ˚C for 1.25 hours to ensure complete 
digestion.  Digested products were evaluated by gel electrophoresis on a 1.2% 
agarose gel.    
 False positives were evaluated by testing twenty-one distinct blood samples 
from different donors for positive RT-LAMP reactions. The maximum rate of 
false positives was calculated by dividing the number of false positives by the 
number of blood samples tested.  
 RT-LAMP Donor Interference Panel. Twenty-one blood samples from 
distinct donors was used to determine if blood from different donors might inhibit 
LAMP.  250 µL of blood was spiked with 104 copies of HIV-1 RNA and added to 
four volumes of lysis solution. Samples were inverted for 15 minutes at room 
temperature and centrifuged at 2,500 x g. The pellet was discarded and the 
supernatant containing nucleic acids was retained for sample processing.  
 Hemoglobin was selectively eliminated from the supernatant with the 
addition of Hemoglobind (Biotech Support Group) through a process described by 
the manufacturer.  Briefly, 250 µL of lysed blood is added to two volumes of 
Hemoglobind, vortexed for 30 seconds, and mixed by inversion for 15 minutes. 
The mixture is then centrifuged at room temperature for 2 minutes at 8600 x g. 
The supernatant is transferred to a new tube and was used for RT-LAMP. 
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RESULTS  
 RT-LAMP Specificity and Sensitivity Using DNA Template. The 
sensitivity and specificity of the assay primers was first evaluated by performing a 
feasibility LAMP experiment using linearized p93IN999 plasmid DNA as 
template and examining the reaction products by agarose gel electrophoresis 
(Figure 2).  The primers successfully detected the presence of three concentrations 
of target DNA: 25 ng (L), 50 ng (M), and 100 ng (H) of p93IN999 template.  
While the outer primers target an approximately 600 nt sequence for 
amplification, the inner primers, which more narrowly select the reaction product, 
produce a 209 nt product (please see LAMP reaction theory, Figure 1). The 
smallest visible band runs at just over 200 bp and bands of increasing size indicate 
LAMP concatemers, which can be collapsed via restriction digestion (Figure 2 
and Figure 7). Additionally, LAMP was performed with a linearized lab stock 
E3L plasmid with no resulting reaction product (data not shown) to test 
specificity.   
 The typical banding pattern associated with LAMP is indicated by the 
arrows (right) in Figure 2. LAMP reactions produce banding patterns reflective of 
concatameric structures generated by loop primers and internal self-priming 
structures (Figure 1). The banding patterns generally, but not always, clearly 
reflect the accumulation of amplified concatameric target sequences. In some 
cases, an atypical LAMP banding pattern was observed as previously reported 
(33).  Atypical banding patterns are generally indicative of contamination and 
when they occur, it is usually in the absence of template.  A no-template control 
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was used for all LAMP assays to address the problem of atypical banding patterns 
and increase the likelihood that observed sample banding patterns were not due to 
contamination. In addition, a no-primer control was added to ensure that stocks 
contained no primer contamination and that template could not self-prime (Figure 
2).  
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Figure 2.  Agarose gel eletrophoresis of LAMP reaction utilizing plasmid 
HIV-1 DNA template. The gel is 1.2% agarose and reaction products were 
visualized utilizing SYBR Green I stain.  Lane 1, 1 kb ladder (NEB). Lane 2, 
no-template negative control. Lane 3, no-primer negative control. Lanes 4-6, 
banding pattern typical of a successful LAMP reaction with a base band of 
an expected size of approximately 210 nucleotides and arrows (right) 
indicating banding of LAMP concatemers. Lane 4, high concentration (H) 
successful LAMP reaction products containing 100 ng of linearized 
p93IN999 plasmid as template. Lane 5, Medium concentration successful 
(M) LAMP reaction containing 50 ng of linearized p93IN999 plasmid as 
template. Lane 6, Low concentration (L) successful LAMP reaction 
containing 25 ng of p93IN999 plasmid DNA as template. Each reaction was 
incubated for 60 minutes at 60 ˚C in a total volume of 25 µL. 
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 RT-LAMP Specificity and Sensitivity Using HIV-1 Subtype C RNA 
Template. The sensitivity and specificity of the assay primers was next evaluated 
by performing LAMP with purified HIV-1 subtype C RNA template and 
examining the reaction products by agarose gel electrophoresis (Figure 3).  The 
primers successfully detected the presence of three concentrations of target RNA: 
105 (Lane 3), 104 (Lane 4), and 103 (Lane 5) copies of virus per reaction. RNA 
dilution stocks were prepared and quantified as described in Materials and 
Methods. RT-LAMP banding patterns can be observed in these lanes, indicating a 
successful amplification reaction. The smallest band, running just below 500 bp, 
is consistent with the expected size of a LAMP product dimer (about 400 nt). In 
this experiment, the limit of detection of purified RNA was 103 copies of RNA 
per reaction, or 40,000 copies per mm3.  No result in Lane 2, no-template control 
indicates that the reaction was likely not contaminated and increases the 
likelihood that the observed banding patterns are a result of specific amplification 
of the target sequence.   
 LAMP banding patterns do not always strictly reflect fragment sizes that 
might be expected from product concatemers of the same size as previously 
described (107). Indeed there are bands between 500-1000 bp that arguably do not 
appear to be strictly trimeric and tetrameric (Figure 3, Lane 3). In order to ensure 
that the reaction products are amplified target sequences, a restriction digest 
utilizing a restriction enzyme specific to the target sequence was performed (data 
not shown). 
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Figure 3. Agarose gel eletrophoresis of RT-LAMP utilizing purified 
HIV-1 RNA template.  The gel is 1.2% agarose and products were 
visualized utilizing SYBR Green I stain. Lane 1, 1 kb ladder (NEB). 
Lane 2, no-template negative control. Lanes 3-8 LAMP reaction 
products containing decreasing concentrations of HIV-1 RNA template, 
from 105 to 100 copies per reaction.  Lanes 3-5, typical LAMP banding 
patterns indicative of successful LAMP reactions. Lanes 6-8, at lower 
concentrations of HIV-1 RNA template LAMP reactions were 
unsuccessful. Lane 9, 1 kb ladder (NEB). Each reaction was incubated 
for 60 minutes at 60 ˚C in a total volume of 25 µL.  
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 Real-time fluorescence of RT-LAMP reactions using SYBR Green I.   
RT-LAMP reactions prepared with varying concentrations of purified  
HIV-1 subtype C RNA (prepared as described in Materials and Methods) were 
visualized utilizing real-time fluorescence (Figure 4). The reactions were 
incubated for an hour at 60 °C and fluorescence was measured utilizing a BioRad 
Mini Opticon Real-time thermal cycler with a SYBR Green I filter. The primers 
successfully detected the presence of four concentrations of target HIV-1 subtype 
C RNA template 103 (red line), 104 (yellow line), 105 (blue line), and 106 (green 
line). Reactions were verified by agarose gel eletrophoresis (data not shown).  
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Figure 4. Real-time fluorescence of LAMP reactions using SYBR 
Green I. Red line, fluorescence tracking of a LAMP reaction 
containing 103 copies of HIV-1 purified RNA template. Yellow line, 
fluorescence tracking of a LAMP reaction containing 104 copies of 
purified HIV-1 RNA template. Blue line, fluorescence tracking of a 
LAMP reaction containing105 copies of purified HIV-1 RNA 
template. Green line, fluorescence tracking of a LAMP reaction 
containing 106 copies of purified HIV-1 RNA template. Each 
reaction was incubated for 60 minutes at 60 ˚C in a total volume of 
25 µL. 
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 RT-LAMP Utilizing Blood Spiked With Varying Concentrations of 
HIV-1 RNA.  In order to further develop the assay for usefulness in resource-
limited settings, RT-LAMP was tested utilizing human blood spiked with varying 
concentrations of RNA (Figure 5). RNA was prepared as described in Materials 
and Methods into serial dilution values ranging between 103-106 copies per 
reaction. In the left gel, successful RT-LAMP reactions were performed using 
purified HIV-1 RNA as template to (Lanes 5, 6).  However, hydroxy-napthol blue 
(HNB), previously reported to be a useful colorimetric indicator for LAMP, 
interfered with RT-LAMP reactions using purified HIV-1 RNA as template (left 
gel, lanes 7-9) (55).  The no-template negative control in the left gel (lane 2) 
shows a smear concentrated below 500 bp, which is perhaps indicative of low-
level contamination.  This nonspecific amplification can be distinguished from 
successful RT-LAMP reactions using SYBR Green I as a fluorescent indicator 
and the unaided eye. 
 It was previously reported that blood inhibits LAMP (33).  Consistent with 
previously reports, when blood was spiked with HIV-1 RNA and added directly 
to the RT-LAMP reaction, no reaction products were produced (right gel, lanes 2-
5).  However, whole blood lysis followed by selective elimination of hemoglobin 
from the sample using an electrostatic polymer, Hemoglobind (Biotech Support 
Group), rescued the RT-LAMP reaction (right gel, lane 9), albeit with a relatively 
low sensitivity of 106 copies per reaction.   
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Figure 5. Agarose gel eletrophoresis of HIV-1 Subtype C RT-LAMP under 
varying conditions. Both gels are 1.2% agarose and were visualized utilizing 
SYBR Green I stain.  Left gel. Lane 1, 1 kb ladder (NEB). Lane 2, no-
template negative control. Lanes 3-6, RT-LAMP reaction products 
containing increasing concentrations of HIV-1 RNA template, from 103-106 
copies per reaction. Lanes 5-6 show positive LAMP banding patterns. Lanes 
7-9, unsuccessful RT-LAMP reactions containing increasing concentrations 
of HIV-1 RNA template in the presence of the colorimetric reporter, 
hydroxy-napthol blue (HNB). Lane 10, 100 bp ladder (NEB). 
 
Right gel. Lane 1, 1 kb ladder (NEB).  Lanes 2-5, RT-LAMP reaction 
products utilizing blood spiked with increasing concentrations (from 103-106 
copies per reaction) of HIV-1 RNA template. Untreated blood inhibited these 
RT-LAMP reactions.  Lanes 6-9, RT-LAMP reaction products utilizing 
blood spiked with increasing concentrations of HIV-1 RNA template, from 
103-106 copies per reaction, and treated with Hemoglobind (Biotech Support 
Group). Lane 10, 100 bp ladder (NEB). Each reaction was incubated for 60 
minutes at 60 ˚C in a total volume of 25 µL. 
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High Sensitivity RT-LAMP Utilizing Blood Spiked With Varying 
Concentrations of HIV-1 RNA.  In order for RT-LAMP reactions to be 
clinically useful, the sensitivity of the assay was further improved.  RT-LAMP 
reactions were performed utilizing blood spiked with varying concentrations of 
HIV-1 RNA as template (Figure 6). Whole blood was spiked with HIV-1 RNA, 
lysed, treated with Hemoglobind to selectively eliminate hemoglobin, and added 
to LAMP reactions.  Two optimizations especially improved reaction sensitivity 
as noted in Materials and Methods.  Increasing AMV RT concentration to 2 U per 
reaction, increasing the template volume added to the LAMP reaction, and 
adjusting primer concentration increased LAMP sensitivity by four orders of 
magnitude (Figure 6, lane 6).    
LAMP was performed using SYBR Green I as a fluorescent indicator.  A 
typical RT-LAMP banding pattern was observed with the smallest clear band at 
approximately 400 bp, consistent with other RT-LAMP reactions observed.  Other 
bands at approximately 600 bp and 800 bp are likely reflective of LAMP 
concatemers. The absence of amplification in the no-template control (lane 2) 
increases the likelihood that the amplification products observed are not the result 
of contamination and that the reaction is specific for HIV-1 subtype C RNA.  
The limit of detection of RT-LAMP was determined to be 102 copies per 
reaction or 4800 copies of viral HIV-1 RNA per mm3.  The same RT-LAMP 
reaction was visualized with the unaided eye (Figure 3, Right).  One challenge 
associated with LAMP is that it is not always possible to easily differentiate 
between input RNA template concentrations based on output reaction 
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fluorescence (Figure 6, right). Tubes were labeled with the amount of purified 
HIV-1 RNA template that was used in each reaction: 105, 104, 103, and 102 copies 
of HIV-1 RNA, respectively. However, fluorescence output did not vary 
significantly with RNA input concentration.  
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Figure 6. Agarose gel eletrophoresis of HIV-1 subtype C RT-LAMP with 
high-sensitivity and naked-eye detection. The gel is 1.2% agarose and all 
reaction products were visualized utilizing SYBR Green I stain.  Left, Lane 
1, 1 kb ladder (NEB). Lane 2, no-template negative control. Lanes 3-6, 
RT-LAMP reactions utilizing human blood spiked with decreasing 
concentrations (105-102 per reaction) of HIV-1 RNA template and treated 
with Hemoglobind (Biotech Support Group). These lanes depict a typical 
LAMP banding pattern with a base band at approximately 400 bp. Right, 
detection of successful RT-LAMP reactions with the unaided eye in the 
same blood samples. Each reaction was incubated for 60 minutes at 60 ˚C 
in a total volume of 25 µL. 
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 RT- LAMP Specificity and Rate of False Positives.  A RT-LAMP panel 
was performed to determine assay specificity and the rate of false positives.  RT-
LAMP assays were prepared using twenty-one blood samples from distinct 
donors spiked with 103 copies of HIV-1 RNA template.  Blood was spiked with 
purified HIV-1 RNA, lysed, and treated with Hemoglobind as described in 
Materials and Methods. The processed blood was added to RT-LAMP reactions.  
LAMP reactions were then digested with PstI and examined by gel 
electrophoresis (Figure 7, even lanes 2-18). Cleavage of intermediate reaction 
products at PstI sites was expected to collapse the LAMP concatameric banding 
pattern, creating two fragments, 52 nt and 157 nt in length. After performing 
digestion and gel electrophoresis, the RT-LAMP banding pattern was observed to 
collapse (even lanes between 2-18) and the larger of the two anticipated fragment 
sizes was observed in lanes that did not contain high concentration of product 
(lanes 2, 4, 12, 14).  The large fragment was not observed in lanes containing high 
concentration of reaction product (lanes 6, 8, 10, 16, 18), perhaps because of 
incomplete digestion or gel overloading.  The collapse of RT-LAMP concatemers 
following digestion with PstI increases the likelihood that the assay is specific for 
HIV-1 RNA.  
 False positive LAMP reactions that produce atypical banding patterns by 
agarose gel electrophoresis have sometimes been reported (33).  Twenty-one 
blood samples were evaluated to determine the rate of false-positives for this 
assay. The results for nine RT-LAMP false-positive test samples are depicted in 
Figure 7 (Figure 7, odd lanes 3-19).  Blood not spiked with HIV-1 was lysed, 
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treated with Hemoglobind, and added to RT-LAMP reactions.  The reaction 
products were analyzed by gel electrophoresis.  No false positive results were 
obtained after performing the panel in triplicate (data not shown). The rate of false 
positives for RT-LAMP with blood samples was determined to be less than 4.8%.  
Further research is needed to establish a confidence range and to more narrowly 
define the rate of false positives. 
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Figure 7. Agarose gel eletrophoresis of HIV-1 RT-LAMP reactions for 
specificity and detection of false positives. The gel is 1.2% agarose and 
reaction products were visualized utilizing SYBR Green I stain. Lane 1 and 
lane 20 are 100 bp and 1 kb ladder (NEB), respectively.  Even numbered 
lanes (2-18) are successful RT-LAMP reactions utilizing blood spiked with 
104 copies of HIV-1 RNA and digested with PstI for 1.25 hours at 37 ˚C. 
In these lanes, LAMP concatemers have collapsed into smaller fragments. 
Odd numbered lanes (3-19) are LAMP reactions performed without 
template HIV-1 RNA. As expected, in these lanes, no reaction products 
were generated by RT-LAMP. Each reaction was incubated for 60 minutes 
at 60 ˚C in a total volume of 25 µL. 
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 RT-LAMP HIV-1 RNA interference panel. An RT-LAMP panel was 
performed to determine if samples of human blood from different donors would 
inhibit the reaction. Twenty-one blood samples from distinct donors were spiked 
with 104 copies of HIV-1 RNA as described in Materials and Methods and added 
to RT-LAMP reactions. Reaction products were then analyzed by gel 
eletrophoresis.  Sixteen of the twenty-one reaction products are shown in Figure 7 
and are representative of the other reactions (data not shown). Lanes 2-17 depict 
typical RT-LAMP banding patterns. The smallest observable fragment is about 
200 bp, as expected based on target amplification design (Figure 1). All of the 
reactions were successful.  On closer inspection, the reaction products in lane 11 
were also successful.  These successful RT-LAMP reactions indicate that the false 
negative rate for this RT-LAMP reaction is less than 1 in 21 tests, or less than 
4.8%.  This finding contributes to a stronger LAMP positive predictive value 
although more research is needed to define significant values for positive and 
negative predictive value for the assay.
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Figure 8. RT-LAMP HIV-1 RNA interference panel. The gel is 1.2% 
agarose and all reaction products were visualized utilizing SYBR Green 
I. Lane 1 and Lane 18 are 100 bp and 1 kb ladder, respectively.  Lanes 
2-17, RT-LAMP reactions utilizing 21 distinct blood samples, each 
spiked with 104 copies of HIV-1 RNA and treated with Hemoglobind 
(Biotech Support Group). Banding patterns reflect positive RT-LAMP 
reactions starting with a base fragment size of about 200 bp. Each 
reaction was incubated for 60 minutes at 60 ˚C in a total volume of 25 
µL. 
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DISCUSSION 
Inadequate viral load monitoring is a critical issue for developing nations.   
The wide-spread implementation of a low-cost viral load test in sub-Saharan 
Africa would likely improve health outcomes for PLWHA, reduce evolution of 
HIVDR, improve infant diagnosis, and improve HIV screening.  
Benefits of LAMP for Resource-Limited Settings. LAMP technology 
has many advantages over conventional viral load technology.  LAMP does not 
require a thermal cycler, computer, or fluorescence detector and therefore requires 
little in terms of equipment capitalization (107).  It can be performed in a water 
bath and produces results in about an hour.  LAMP is less sensitive to inhibitory 
agents than PCR and therefore requires less sample preparation (74). The fact that 
LAMP uses six primers that bind to eight specific and distinct target sequences 
reduces the likelihood of false positive test results.  Because LAMP produces high 
concentrations of DNA product, successful reactions have be visualized with the 
unaided eye by means of fluorescence using SYBR Green I or calcein, or by 
turbidity as a consequence of high concentrations of magnesium-pyrophosphate 
by-product (33, 55, 102).  Further, a growing body of literature is validating 
LAMP as an effective tool for diagnosing viral, bacterial, and fungal infections in 
a variety of plants and animals (59, 105, 109, 124). 
This study extends the adaptation of LAMP for the detection of HIV-1 
(34).  Specifically, we provide an alternative approach to sample preparation and 
demonstrate that LAMP can be used to detect HIV-1 subtype C.   
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The analytic sensitivity of assay was measured by spiking whole blood 
with known concentrations of RNA based on spectrophotometric analysis. The 
sensitivity of the assay was determined to be between 4,800 copies of RNA per 
mm3 (Figure 6).  The rate of false positives was determined to be less than 4.8% 
and LAMP was specific for HIV-1 subtype C (Figures 6, 7).  While our findings 
demonstrate a lower sensitivity than conventional viral load testing (for which the 
limit of detection is 40-50 copies per mm3) or than that which has been previously 
published, recent studies suggest a wider range for the practical definition of 
virologic failure, between 1,000-10,000 copies per mm3 (9, 79, 82, 119).  With 
this alternative definition for virologic failure, the RT-LAMP assay we have 
developed possesses sensitivity within the required range for use as a public 
health screening tool.  
Limitations of RT-LAMP for Resource-Limited Settings. The RT-
LAMP assay has several drawbacks when considering resource-limited settings. 
RT-LAMP requires significant validation with HIV-1 subtypes before it can be 
widely used in sub-Saharan Africa.  Problems with false-positive results that must 
be verified by gel electrophoresis will need to be addressed before broad adoption 
as a public health tool in any locale.  Additionally, LAMP requires significant 
formal validation if it is to be used as a government-approved test in almost any 
developing country. Since every government in sub-Saharan Africa is receiving 
foreign aid to address internal AIDS healthcare problems, it will likely be 
necessary for LAMP to be validated by a US or European regulatory body.  
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Additionally, sample preparation remains a problem.  It has not yet been 
shown that heat-pretreatment of samples is a consistently effective approach to 
sample preparation for LAMP.  In the absence of heat-treatment, multi-step 
centrifugation approaches must be used.  These approaches do not lend 
themselves to resource-limited settings since they require power, relatively 
expensive equipment, and skilled labor. Finally, the LAMP assay is not designed 
to be a quantitative test.  Consequently, it must be refined significantly to produce 
high-fidelity binary results or a range of results.  
Despite these limitations, RT-LAMP shows promise as an inexpensive 
public health assay for developing countries.  With more development and 
validation, our HIV-1 subtype C RT-LAMP assay may be useful as a screening 
assay for HIV-1 in resource-limited settings.  Given that patient viral load varies 
between 103 and 108 copies per mm3 during the acute phase of infection, this 
assay could be used to screen for infant infection, virologic failure, and as a 
confirmatory HIV-1 test. 
Limitations of the Proof-of-Concept RT-LAMP Approach. Blood 
samples from twenty-one patients were spiked with RNA and tested for 
compatibility with LAMP. This proof-of-concept approach was effective for 
proving the detection of HIV-1 subtype C with custom primers.  However, this 
approach has several weaknesses.  Although we have detected HIV-1 RNA in 
human blood with RT-LAMP, we did not detect RNA present in virions and 
inside cells, as is the case for in vivo infection. This is a necessary next step for 
assay validation.  Indeed, it would be ideal if blood samples could come fresh 
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from a variety of HIV-1 subtype C donors with certified viral loads.  Then RT-
LAMP could be tested with a variety of HIV-1 strains prevalent in sub-Saharan 
Africa and results could be compared to the results of gold-standard testing.  
Moreover, this assay did not reproduce results previously published 
regarding the heat-treatment of samples.  Heat-treatment at 95-100 ˚C has been 
shown to be a sufficient sample preparation step for LAMP (34).  However, in 
this study, heat treatment resulted in reactions that did not produce amplification 
products.  One explanation for this result is that HIV-1 nucleic acid from HIV-1 
infected blood samples would be protected by cellular materials (provirus) or a 
protein nucleocapsid (virions).  The RNA added to blood samples in our study 
was ‘naked’ and may have been degraded by exposure to high temperature.  
Untreated blood inhibits RT-LAMP (Figure 6, lanes 3-6) and heat-treating 
blood was not effective in producing successful reactions with our system (data 
not shown).  Consequently, we sought an agent to eliminate biomolecules present 
in blood that were interfering with RT-LAMP.  Among the most commonly 
reported blood-based inhibitors of PCR is hemoglobin (5, 6).  Consequently, we 
sought a reagent to remove hemoglobin from blood samples following the 
addition of RNA.  Hemoglobind (Biotech Support Group), an elastomeric poly-
electrolyte is promoted as having high specificity for binding hemoglobin. 
Hemoglobind initially reduced the sensitivity of the assay (Figure 5, right gel, 
lanes 6-9), but the assay was ultimately optimized for better sensitivity using 
Hemoglobind (Figure 6, left gel). 
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There are two significant problems with using Hemoglobind in developing 
countries.  First, a prerequisite step for the use of Hemoglobind is whole blood 
lysis, which requires some technical skill and a low-speed centrifuge. Secondly, 
extraction of hemoglobin with Hemoglobind involves another few technical steps 
with moderately high-speed centrifugation (8,600 x g).  
If the use of Hemoglobind can be proven effective for HIV infected blood 
samples, it would represent a significant advance over far more complicated 
nucleic acid extraction techniques that could not be implemented in rural Africa in 
the foreseeable future.  Ideally however, a rural viral load assay would depend as 
little as possible on proprietary products or processes that require centrifugation.  
With limited blood samples, the false positive rate for our assay was 
determined to be below 4.8% (Figure 7).   With future research, that window can 
be narrowed and more completely defined with a confidence interval.  Likewise, 
the false negative rate was determined to be below 4.8% (Figure 8).  
A benefit of the RT-LAMP assay is that output fluorescence signal is 
strong enough to be read without UV irradiation by the unaided eye.  Importantly, 
a simple cell-phone camera photo can be used to communicate results (Figure 6, 
right).  This aspect of the RT-LAMP assay is important for resource limited 
conditions, where laboratory equipment is difficult to find, but cellular phones are 
ubiquitous. However, there is not a strong association between fluorescence 
output signal and input target RNA levels (Figure 6, right).  An improvement to 
the assay would be a dose-response characteristic for input RNA. One reason for 
the lack of correlation may be limiting concentrations of reactants, including 
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SYBR Green I.  Increasing the concentration of SYBR Green I may permit 
increased fluorescence for samples with greater input RNA and therefore greater 
product. Other reactants that may be limiting, including DNTPs, could be tested 
for optimization of this assay characteristic. 
 The RT-LAMP assay was performed in the presence of hydroxy-napthol 
blue (HNB) as a colorimetric detection agent instead of SYBR Green I (Figure 5). 
While others have reported success in using HNB as an alternative reporter for 
LAMP, we found that HNB interfered with the LAMP reaction. Visualization of 
successful LAMP reactions with HNB was problematic since the addition of 
whole blood discolored the samples such that color change was difficult to 
differentiate and HNB appeared to have an inhibitory effect on the reaction 
(Figure 5, lanes 7-9).    
In summary, RT-LAMP is an inexpensive, rapid assay for the detection of 
HIV-1 subtype C RNA in human blood. With improvements in sensitivity, sample 
processing, and more validation, this RT-LAMP assay may hold promise as a 
rapid qualitative assay for viral load screening in developing countries.  
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Chapter 2 
ASSESSING BARRIERS TO THE ADOPTION OF MEDICAL 
TECHNOLOGY IN NORTHERN TANZANIA 
INTRODUCTION 
In order to understand whether or not a new technology can be effectively 
used in a developing country, it is necessary to review the local context, including 
organizational structures and operations, local priorities, and local culture.  An 
HIV-1 viral load assay has been developed at Arizona State University according 
to engineering parameters that describe device use in resource-limited settings.  
While international attention has focused on the development of such an assay for 
developing countries, it is not clear that local medical providers will be willing to 
adopt this new technology. Provider attitudes can be surveyed regarding HIV and 
HIV services, the working environment, priorities and obligations, and the results 
of surveys can be used to inform approaches for the delivery of new technology.  
Country Selection for Novel Viral Load Testing. In order to assess 
practical and cultural barriers to adoption of a new viral load assay in sub-Saharan 
Africa, a low-income country in sub-Saharan Africa, Tanzania, was selected for 
field surveying.  Country selection criteria included low health infrastructure and 
personnel based on UN human development report data, political stability, a 
mature HIV epidemic, and a national program for provision of free HIV 
medicines. 
 Tanzania Background Information. Tanzania is located in East Africa, 
bordering the Indian Ocean, Kenya, Burundi, the Democratic Republic of the 
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Congo, Mozambique, Zambia, and Uganda.  The population of Tanzania is 
growing by about one million people per year and is about 43 million people, of 
whom about 2.2 million are estimated to be HIV positive (134).  While national 
prevalence is reported to have dropped to 5%, it is essential to acknowledge 
variations masked by aggregate national reporting values.  
 The majority of HIV transmission in Tanzania is heterosexual (almost 
80%), although MTCT represents a significant source of infection (5%). Other 
forms of infection, including IDU, and male homosexual sex accounts for the 
remaining 15% of transmission.   
 Poverty in Tanzania. Poverty is a critical issue in Tanzania. More than 
two-thirds of Tanzania’s people live on less than $10 USD per day.  Poverty 
contributes to the HIV epidemic in many ways.  First, poverty creates conditions 
that drive women into sex work, placing them at higher risk for contracting HIV. 
Poverty differentially drives men and women to urban areas from rural homes to 
look for additional resources.  Once there, women in poverty are at risk for 
initiation to sex work (44). Further, women in rural areas are driven to take 
additional sexual partners in order to meet basic needs, giving rise to the “sugar 
daddy” phenomenon (87).  This practice puts women at increased risk for 
infection with HIV and other sexually transmitted infections.  
 Men are subject to the forces of poverty as well.  Poverty drives the migrant 
labor in sub-Saharan Africa to which the movement of HIV-1 across the continent 
has been attributed (42, 88, 126). It has been documented that migration work and 
long periods away from home create the conditions for high-risk infidelity (73).  
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Several studies have been conducted among married male truck drivers in Africa 
who hire prostitutes or have mistresses while away from home (94, 96). Men who 
participate in this behavior put their spouses and children at risk for HIV 
infection.  
 Gender Inequity In Tanzania. Women married to men who engage in 
migrant labor have little recourse in protecting themselves from HIV infection.  
Married women have little leverage to negotiate condom use and may face 
domestic violence as a consequence of voicing a concern (43).  Indeed, in one 
study, 52% of HIV positive women had experienced domestic violence, and 44% 
had experienced sexual violence in their relationship (89).  Even if a women 
suspects that her husband has not been faithful, she lacks the power to resist sex 
and is also driven by cultural custom to have children.  
 Married women frequently have more to lose than men in the event of a 
positive diagnosis.  HIV positive women have been stoned to death in the last 15 
years, have been ejected from their homes and communities, and face 
extraordinary barriers to accessing health services (36, 89, 138).  
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 Stigma Associated with HIV. Stigma associated with HIV and AIDS is a 
serious problem in Tanzania.  Stigma acts as a potent force in preventing people 
from talking openly about HIV and reduces the likelihood that an individual will 
seek testing for fear that a positive diagnosis will mean a social and physiological 
death sentence.  Further, people living in rural areas who want to be tested for 
HIV in Tanzania frequently travel hours or days longer to visit a regional hospital 
far from home. It has been reported that they fear that workers in the hospital who 
live in their community will disclose their status. 
 This concept of false anonymity is central to the problem of HIV and AIDS 
in Tanzania. Public health interventions that have acknowledged this idea have 
been very successful.  Mobile voluntary testing and counseling (VCT) teams have 
been extraordinarily successful in HIV testing outreach.  People in Tanzania are 
hesitant to take an HIV test in part because they fear a lack of resources for 
treatment and are concerned about the ‘next step’.  It is a testament to the power 
of anonymity in Tanzania that mobile VCT programs have been wildly successful 
despite the fact that the vast majority of mobile VCTs in Tanzania do not offer 
services beyond testing and counseling.  
  Stigma also complicates adherence to antiretroviral treatment. PLWHA 
fearing stigma regularly hide pills to keep friends and family from discovering 
their status, make excuses about days when they are visiting a health center, and 
go to great pains to stay healthy to as not to rouse suspicion about their status.   
 Resource Limitations. Resource limitations in Tanzania create special 
challenges for PLWHA. Today there are still problems that keep PLWHA from 
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accessing cART in Tanzania. First, individuals have to find a truly anonymous 
HIV test.  If determined to be positive, the next barrier to care is often time, 
money, and transport to a specialized regional health center for CD4 evaluation.  
The Tanzanian healthcare system is under extreme pressure such that patients are 
frequently sent home before being seen by a healthcare provider.  For those who 
traveled for a day to reach the hospital, going home and coming back is not a 
feasible option.     
 Public statements about access to cART in sub-Saharan Africa suggest that 
care and therapy are offered free of charge to HIV positive Africans.  This is not 
strictly true.  If a person has received a positive ELISA and can be seen by a 
doctor at a regional center, he or she will need to pay to “open a file.”  Further, 
sometimes health providers charge graft in order to see patients ‘first’.  This 
practice has been a part of Tanzania life for over twenty years (30).  Patients who 
receive cART must return to the hospital within thirty days to renew their supply 
of drugs.  
A significant aspect of corruption in healthcare is that there are not enough 
healthcare providers in Tanzania (103).  The so-called ‘brain drain’ attracts top 
medical doctors and nurses to industrialized nations after the completion of 
studies in Tanzania (61).  Healthcare providers who elect to remain in Tanzania 
face incredible patient loads, inadequate laboratory testing for diagnosis, 
inadequate drugs for treatment, and poor pay.    
 New understandings of the social factors that provide some measure of 
protection from virologic failure provide hope that simple, inexpensive behavioral 
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changes can be made to save lives.  First, public disclosure of status has been 
shown to be a protective factor. Men and women who disclose their status are less 
likely to fail first-line cART, perhaps because they have greater social support and 
face fewer barriers in returning regularly to the hospital for drugs.  Free 
antiretrovirals provide protection against virologic failure, likely because 
PLWHA in Tanzania can’t consistently afford cART. Free transport has also been 
shown to be an important factor in preventing virologic failure.  If a person can’t 
afford the necessary transport to visit the hospital for a cART refill, it is likely that 
adherence will be a problem.   
Ethical Considerations. Tanzania is ideally situated as a test case for 
alternative viral load technology. It is estimated that 2.6 million people are 
infected with HIV in Tanzania, although national prevalence has dropped from 
7% to 5% in the last three years, in part due to the proliferation of cART (128, 
134). Tanzania’s healthcare infrastructure is among the worst in the world and the 
additional burden placed on an already stressed system by HIV cases makes it 
ideally placed to observe an effect resulting from technological innovation (136).  
Further, because it represents a significant burden on the system, it is anticipated 
that medical providers will have an interest in sharing their opinions and feelings 
regarding HIV infection and may be more likely to consider using a new viral 
load assay.  
Because Tanzania is in a healthcare crisis, there are ethical considerations 
specific to a survey of medical staff in the country. In particular, disruptions to 
health services by project staff must be minimized.  Disruption is virtually 
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unavoidable since project staff distribute surveys at medical clinics during 
operating hours when sick patients are requesting services.  The survey must 
therefore be very brief so as not to take time away from sick patients.  
Theoretical framework.  There are two theoretical frameworks that 
might inform activities associated with health-related technology transfer to 
Africa, the Technology Acceptance Model (TAM) and the Theory of Planned 
Behavior (TPB).  TAM seeks to assess the likelihood that a given user will adopt 
a new technology and was born out of a need to understand whether or not users 
would adopt computers.  TBP is an extension of the Theory of Reasoned Action, 
which posits a correlation between behavioral intention and action.  According to 
TPB, behavioral intention is determined by combining users’ attitudes toward a 
behavior, the subjective norms in the users’ environment, and perceived behavior 
control, which measures the extent to which a user believes that he or she has the 
agency necessary to carry out the behavior.   
The primary components of TAM are perceived ease of use and perceived 
usefulness.  In most studies utilizing TAM, the technology is either already well 
understood among the user population or the technology has already been 
implemented as a pilot (84, 123).  The adoption of a complex technology with 
which most regional medical providers in Tanzania are not familiar does not 
appear to be a good fit for the TAM.  Additionally, the TAM has not been shown 
to accurately predict user adoption in health-related systems (23, 123).  There is a 
dearth of validated TAM instruments available for evaluating health technology 
acceptance in developing countries among providers.  Moreover, the brevity 
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requirement places limitations on the capacity of the instrument to both inform 
users about the technology and inquire about perceived usefulness.  
The TPB can be used to inform this study through an understanding of 
participant attitudes toward the behavior of providing a viral load test to clients.  
However, there is no precedent for TPB to be used in the context of health 
technology transfer to a low-resource country.  The validation and use of TBP for 
the purposes of this study extend beyond the scope of the project. 
   
MATERIALS AND METHODS 
 Data.  This purpose of this project is to determine what local barriers 
might prevent the adoption of a new assay for HIV in Northern Tanzania by 
surveying medical providers working in Northern Tanzania. An institutional 
review board (IRB) at Arizona State University (ASU) approved all human 
subjects activities associated with this study in the fall of 2010 (ASU IRB 
protocol 1009005476).  
 Participants. Study participants are medical providers actively working in 
Northern Tanzania.  Participants were recruited at their respective places of 
employment throughout Northern Tanzania.  Criteria for participation in the study 
was being currently employed in the clinical care of people living in Tanzania, 
working in a peri-urban or rural clinic, being at least 18 years of age, and 
speaking English.   
Individuals who showed interest were invited to participate in a study 
examining medical provider impressions of HIV and HIV-related technologies 
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and services in Northern Tanzania.  Candidates were informed that participation 
was voluntary and that they could terminate their participation in the study at any 
time. If candidates expressed interest in the study, they were informed that they 
would each be provided with a phone card worth TSH 5,000 as a token of 
appreciation for donating time to the study. Candidates were informed that the 
study is an anonymous investigation and that no name information would be 
collected. Candidates were provided an IRB-approved cover letter explaining the 
research project and provided with contact information for the study PI and the 
ASU IRB. Verbal consent was collected if candidates wished to proceed with 
participation in the study.  
Participants for the survey were doctors, medical officers, assistant 
medical officers, nurses, nurse midwives, medical assistants, laboratory 
technicians, laboratory assistants, and HIV counselors actively working in 
healthcare in Northern Tanzania. 
Instrument. There are no published validated instruments that evaluate 
technology adoption in a healthcare setting in developing countries.  The 
technology acceptance model (TAM), an extension of the theory of reasoned 
action (TRA) offers some validated instruments for evaluating technology 
acceptance.  However, the key components of TAM, evaluating perceived ease of 
use and usefulness require for participants to be familiarized with the technology 
in question.  Further, published methods and instruments did not adequately 
conform to the requirements of this study, namely, that medical providers not be 
required to spend more than 15 minutes per survey and that project staff not be 
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required to interview participants.  These ethical measures were taken to ensure 
minimal disruption to the critical medical services provided by healthcare workers 
already overwhelmed by a system in crisis.  
Consequently, a new self-report instrument was designed to capture 
barriers that medical providers in Northern Tanzania might face in the adoption of 
new medical technology, particularly for the care and treatment of PLWHA.  The 
instrument is a two page, 20-question survey containing short answer, Likert-scale 
multiple choice, and fill-in questions.  The instrument collects no personally 
identifying information.    
Survey and interview approaches were considered when designing data 
collection strategies.  There were several challenges associated with individual or 
group interview-based approaches.  An interview would likely take more clinician 
time than was considered to be ideal for a pilot study. Recorded interviews in 
Tanzania would likely be considered formal and particularly in the case of group 
interviews may generate reduced participation, unwanted social desirability, and 
interviewer distortion.  Additionally, there were feasibility issues associated with 
an interview approach. Additional personnel are often required to assist in note-
taking or cultural interpretation.  Additional staff require additional resources in 
the form of salary, training time, and project coordination overhead.  
The self-report survey approach gave providers maximum control over the 
amount of time spent on the survey, which is important for reducing impact to 
wellness services.  Self-report surveys took relatively little time to complete and 
could be administered in a very short period of time to a large number of 
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providers.  Interest in participating in the survey was relatively high and there was 
little concern regarding false respondents.  The improved feasibility of using self-
report surveys was the driving motivation for choosing self-report surveys over 
interview-based surveys. 
Field Researchers. Study staff certified for human subjects research 
performed recruitment, data collection, storage, and analysis. Surveys were left 
with participants and the collection date and time was established collectively by 
participants.  All interactions were conducted in English.  If a candidate did not 
speak English, they were not invited to participate in the study. Each survey took 
10 minutes on average to complete.  
Sample Selection. Sample selection occurred both at the clinic level and 
at the individual level. Sampling for both was non-random. Instead, the study 
sought to capture as much coverage of medical clinics and personnel in one area 
of Northern Tanzania as possible.  Coverage reached 100% in some areas and was 
estimated to be over 80% in some areas. 
Because there is no directory of medical clinics or health services in 
Tanzania, it was necessary to engage in field mapping and resource surveying to 
discover clinic locations. This was accomplished by means of several methods, 
including snowball sampling at each medical clinic, requesting directions and 
information from local people, and surveying by driving all the roads in a given 
area.  Because medical clinics are almost uniformly found near roads in Northern 
Tanzania, the latter method proved very useful in locating clinics for which there 
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wasn’t local knowledge or where snowball sampling failed to discover rural 
clinics.   
Inclusion criteria for clinics was the presence of medically trained clinical 
staff, adequate laboratory space to incorporate LAMP viral load testing, and 
permission from the doctor in charge for staff participation.  
Random sampling at the individual level would have been problematic in 
Tanzania.  Arbitrarily choosing a subset of individuals who can participate, share 
their voice, and receive a reward is seen as inherently unfair.  Indeed, even when 
distributing phone cards, project staff were asked to split 5,000 TSH phone cards 
into smaller vouchers so that study participants could share with medical staff 
who could not participate.  The most frequent reason for non-participation was 
not being present at work on the day that surveys were distributed. Most medical 
providers in each clinic expressed interest in participating in the project.  
Data Collection. Surveys were prepared and taken to field sites in 
Northern Tanzania. A meeting was held with the doctor in charge of each medical 
clinic to request site participation in the clinic.  Permission must be given by the 
doctor in charge so that study personnel could be present in the clinic for research 
purposes. Clinic staff were invited to participate in the study.   
At the request of the IRB, a signed informed consent form was not used in 
an effort to protect the identity of participants.  Instead, a cover letter was given to 
each participant.  All questions were answered on site.  Additionally, participants 
were informed that they could contact the principal investigator or the ASU IRB 
via the contact information on the cover letter. 
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Participants who provided verbal informed consent took an individual-
level survey and a consensus was reached regarding an appropriate collection 
time for the surveys. Study staff returned to each site at the prescribed time to 
collect surveys and distribute a 5,000 TSH phone card to each participant as a 
token of appreciation.  
Surveys were then hand-carried to a secure location and kept under lock 
and key until they could be hand-carried back to the United States.  Surveys are 
stored at Arizona State University in a locked cabinet in a secured facility.  Only 
researchers approved by the ASU IRB have access to raw survey data.   
Variables and Measures.  Variables included respondent gender, and 
education level, whether the clinic was located in a rural or urban area, and 
whether the clinic was a government, for profit, or not-for profit institution.  
Participants were queried for information about service populations, 
services offered in relation to HIV, testing and treatment priorities, willingness to 
adopt a new HIV viral load test, and for attitudes about HIV transmission.    
Participants were queried about which HIV tests they offer.  Responses 
were fill-in and were re-coded into one of two categories, ELISA or non-ELISA.  
100% of respondents indicated that they provide ELISA HIV tests.  
Participants were queried for their belief in the accuracy of ELISA HIV 
tests with the question, “Are HIV tests in your clinic accurate or are they 
sometimes wrong?” The Likert scale answers are 1=Often Wrong, 2=Sometimes 
Wrong, 3=Accurate, and 4=Very Accurate. 
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  Belief regarding the morality of HIV transmission was evaluated with the 
question, “HIV is usually transmitted as a result of immoral behavior.”  The 
Likert scale answers are 1=Strongly agree, 2=Agree, 3=Disagree, 4=Strongly 
Disagree.  
Participant religious beliefs in regards to HIV were evaluated with the 
question, “Using condoms is against God”. Likert scale answers are 1=Strongly 
agree, 2=Agree, 3=Disagree, 4=Strongly Disagree.  
 Willingness to adopt a viral load assay for HIV was evaluated with a two-
part question, “Would you use a new viral load test if it could deliver results in 
one hour and cost 15,000 TSH per test?”  and “Please explain your response”.  
The answers to the former question are 1=Yes and 2=No.  
Participants were asked about the reasons why HIV is a problem in 
Tanzania with the question, “Why is HIV a problem in Tanzania?”  Answers were 
essay or fill-in and were coded into four broad categories: ‘stigma’, ‘poverty’, 
‘education’, and ‘other’.  
Data Analysis. This study evaluates Tanzanian medical providers’ 
willingness and ability to adopt new medical technology. The analytic method 
utilized is an independent sample t-test with descriptive analysis and frequency 
tables.   
 
RESULTS 
Clinic Locations and Staffing. Fifty-one clinics were discovered, 
predominantly in the peri-urban area of the town of Arusha in the Arusha Region 
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of Northern Tanzania (Table 2). Through brief conversations with clinic staff, 
estimates for the number of staff workers were developed (Table 2, columns MD 
through LA).  The designations include MD for medical doctors, TN for trained 
nurses, MA for medical assistants, MO for medical officers, NM for nurse 
midwives, LT for laboratory technologists, and LA for laboratory assistants.   
Medical Doctors (MD) receive training similar to that provided doctors in 
industrialized nations. Trained Nurses (TN) spend three years in a training 
program followed by a year of practicum.   Medical Assistants (MA) usually 
complete a one-year certificate program.  Clinical Officers (CO) complete a three-
year course in clinical medicine. Assistant Medical Officers (AMO) complete the 
clinical officer training followed by another 2 years of training.  Nurse Midwives  
(NM) complete a one-year practicum-based certificate program.  Laboratory 
Technologists (LT) usually complete two- to three years of training while 
Laboratory Assistants (LA) complete a one-year certificate program. 
Clinic Services. Services offered by clinics in Northern Tanzania vary 
significantly in service offerings (Table 3).  If a clinic was found in an urban area, 
the prefix designator “AR” (for Arusha) was added to the name of the area in 
which the clinic is located.  Among the most common medical offerings found in 
Northern Tanzania was pharmacy service without capacity for clinical visitation 
or testing.  These sites could not be included in this investigation because 
pharmacies lacked medically trained staff and space for laboratory equipment.    
 
  
  75 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Staffing of mapped medical clinics in Northern Tanzania. MD (Medical 
Doctor), TN (Trained Nurse), MA (Medical Assistant), MO (Medical Officer), 
NM (Nurse Midwife), LT (Lab Technologist), LA (Lab Assistant).   
No. MD TN MA MO NM LT LA 
1 1 3 0 0 0 2 0 
2 3 8 0 0 0 2 0 
3 2 4 0 0 0 0 0 
4 7 8 0 0 0 1 0 
5 4 8 0 0 0 1 0 
6 3 1 3 0 0 1 1 
7 4 7 0 0 1 0 0 
8 3 6 0 0 0 0 0 
9 3 4 4 0 2 1 0 
10 1 2 1 0 3 1 1 
11 0 3 0 0 0 0 0 
12 3 30 0 8 0 2 0 
13 4 2 0 0 0 1 0 
14 2 3 0 0 0 0 0 
15 1 2 0 0 0 1 0 
16 6 6 0 0 0 1 0 
17 2 3 0 0 0 1 0 
18 5 10 0 0 0 0 0 
19 5 0 0 0 0 0 0 
20 3 6 0 0 0 1 0 
21 3 6 0 0 0 1 0 
22 2 5 0 0 0 2 0 
23 2 3 0 0 0 0 0 
24 2 3 3 0 0 5 0 
25 2 7 0 0 0 2 0 
26 2 9 0 0 0 0 0 
27 0 1 0 0 0 1 0 
28 2 2 0 0 0 1 0 
29 1 1 1 0 0 1 0 
30 1 2 0 0 0 1 0 
31 2 5 0 0 0 0 0 
32 1 1 0 0 0 0 0 
33 3 3 0 0 0 1 0 
34 1 2 0 0 0 1 0 
35 0 2 0 0 0 0 0 
36 1 2 0 0 0 0 0 
37 2 2 0 0 0 0 0 
38 1 0 0 0 0 0 0 
39 2 3 0 0 0 0 0 
40 3 6 0 0 0 0 0 
41 2 4 0 0 0 0 0 
42 3 ND 0 0 0 0 0 
43 1 2 0 0 0 0 0 
44 0 0 0 0 0 2 0 
45 2 4 0 0 0 1 0 
46 2 6 0 0 0 0 0 
47 1 4 0 0 0 0 0 
48 1 3 0 0 0 1 0 
49 3 3 0 0 0 0 0 
50 3 4 0 0 0 1 0 
51 1 2 0 0 0 1 0 
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Table 4. Locations and services offered by health providers in Northern Tanzania. 
No. Lab Pharmacy Location 
1 Yes Yes Moshono 
2 Yes Yes  AR-Ngarenaro  
3 Yes Yes AR-Central 
4 Yes Yes AR-Central 
5 Yes Yes AR-Sakina 
6 Yes ND Meru Leganga 
7 Yes Yes AR-Old Arusha 
8 ND ND AR-Old Arusha Rd 
9 Yes Yes AR-Unga ltd 
10 Yes Yes AR-Mianzini/Sanawari 
11 Yes No AR-Kilombero 
12 Yes ND AR-Levolosi 
13 Yes Yes Sekei/Nguelelo 
14 Yes No Nguelelo 
15 Yes Yes Kijenge 
16 Yes Yes Soweto 
17 Yes Yes AR-Stadium 
18 Yes Yes  AR- Posta  
19 ND ND AR - Tenki La Maji 
20 Yes Yes Kijenge Chini 
21 Yes Yes Kijenge 
22 Yes Yes AR-haileslesi 
23 ND ND Usa River 
24 Yes Yes AR - Sabena 
25 Yes Yes AR-Kaloleni 
26 ND ND Usa River 
27 Yes Yes Sekei 
28 Yes Yes AR-Sanawari 
29 Yes  Yes Manyara 
30 Yes Yes Kisongo 
31 ND Yes Kisongo 
32 ND ND Tengeru 
33 Yes Yes Moshono 
34 Yes Yes AR- Levolosi 
35 Yes ND AR-Sanawari 
36 No No AR- Leyaro St 
37 Yes ND Manyara 
38 Yes ND AR-Central 
39 Yes ND Manyara 
40 Yes ND AR-Central 
41 Yes ND Manyara 
42 Yes ND Manyara 
43 Yes No Njiro 
44 Yes No Ngaramtoni Juu 
45 Yes Yes Ngaramtoni Juu 
46 Yes ND AR-Unga Ltd 
47 Yes Yes Sanawari 
48 Yes Yes AR-Central 
49 No Yes Kisongo 
50 Yes Yes AR-Mianzini 
51 Yes Yes Ngaramtoni Juu 
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Responses rates.   The survey was provided to 35 clinics out of 55 total 
clinics (Table 4).  The primary reason for clinic non-participation was project 
budget limitation on transport.  A few clinics were mapped early in the project but 
later could not be located. One clinic refused to participate on the basis of 
religion.  Individuals participated at an estimated rate of 24%. The number of 
clinic staff at each clinic was difficult to estimate.   
 Clinical Officers represented the most significant category of responder, 
where 35% of all medical officers participated in the study. By proportion, nurses 
represented the greatest fraction of responses among surveys gathered. 
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Study Response Rates     
      
Total Number of Clinics (Est.)   55 
Number of Clinics with Responders   35 
Total Clinic Response Rate   64% 
      
Total health workers (Est.)   349 
Number of individual respondents   83 
Total individual response rate   24% 
      
Individual Response Rates by Title (Est.)   
Doctor   11% 
Nurse   9% 
Medical Assistant   27% 
Medical Officer   35% 
Nurse Midwife   57% 
Lab Technologist   19% 
Lab Assistant   100% 
      
Sample Proportion by Title     
Doctor   12% 
Nurse   20% 
Medical Assistant   5% 
Clinical Officer   13% 
Nurse Midwife   5% 
Lab Technologist   8% 
Lab Assistant   4% 
 
Table 5. Survey response rates based on number of participating clinics and 
individuals.  Due to dual employment and difficulty in assessing an accurate 
number of health workers, total number of individuals and clinics are estimates. 
Individual response rates are indicative of the proportion of health care workers 
who responded, given the total number in the area.  Sample proportion indicates 
the proportion of the respondent sample each healthcare role comprises.
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Responses to research questions.  Medical providers were asked “Would 
you use a new viral load test if it could deliver results in one hour and cost TSH 
15,000 per test?”  The overwhelming majority, 74.6% of respondents, answered 
‘No’ (Table 5). Comments provided insight as to the primary reason for their 
answers: at 15,000 Tanzanian Shillings (approximately $12 USD), the test was 
considered to be too expensive.  One response states that,  
“15,000 IS EXPENSIVE FOR OUR COMMUNITY B'SE WE SERVE MOST OF 
PEOPLE LIVING WITH UNDER 1 DOLLAR PER DAY” 
Clearly, although the price of the viral load assay has been reduced by almost an 
order of magnitude, the cost is still too high for clinicians surveyed in Northern 
Tanzania. 
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Respondent Answers     
      
Would you use a new viral load test if it could deliver results in one 
hour and cost TSH15,000 per test? 
    
Respondents answering “Yes”   25.4% 
Respondents answering “No”    74.6% 
    
Reasons for those Answering “No”:     
    
“15,000 IS EXPENSIVE FOR OUR COMMUNITY B'SE WE SERVE 
MOST OF PEOPLE LIVING WITH UNDER 1 DOLLAR PER DAY” 
“BECAUSE MANY CLIENTS WHO ARE COMING HAVE LOW  
ECONOMIC STATUS, THEY CAN'T AFFORD THE PRICE" 
“BECAUSE WE CANNOT AFFORD THE COST”  
“BUT STILL NOT AFFORDABLE” 
“COST IS HIGHER CLIENT ARE NOT AFFORD” 
 
“IS TOO EXPENSIVE”  
“IS VERY EXPENSIVE”  
“IT IS VERY EXPENSIVE”  
“IT WOULD BE FAST AND BEST BUT NOT ALL PATIENTS 
WILL AFFORD THE CHARGES”  
“MOST HIV POSITIVE PATIENTS WOULD NOT BE ABLE TO 
AFFORD”  
“MOST OF PATIENTS WITH HIV/AIDS ARE VERY POOR SO 
THEY CAN NOT AFFORD AND MANY OF THEM WILL DIED”  
“MOST OF THE PATIENT CAN'T AFFORD“ 
 
Table 6. Frequency of responses to the primary research question. Responses 
were recorded to the question “Would you use a new viral load test if it could 
deliver results in one hour and cost TSH15,000 per test?” In addition to a binary 
response, many healthcare workers added comments.  For the respondents 
answering ‘No’, representative quotations describing their reasons for answering 
in the negative are provided.  
  
Perceived Accuracy of HIV tests.  Clinicians were surveyed for their 
perspectives regarding the accuracy of ELISA sero-status HIV tests.  89% of 
respondents indicated that the test is either ‘accurate’ or ‘very accurate’ (Table 6). 
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ELISA HIV-1/2 tests have been reported to have relatively poor performance in 
East Africa and even at their best, have a false positive rate of 1 per 1000 tests. 
Questions Regarding Condom Use, Religion, HIV Transmission, and 
Morality.  Clinicians were surveyed for their perspectives regarding whether 
condom use is against God with the question, “Using condoms is against God” 
(Table 7, top half). 27% of respondents ‘strongly agree’ or ‘agree’ that using 
condoms is against God. Clinicians were also surveyed for their perspective on 
HIV transmission and morality with the question, “HIV transmission usually 
occurs as a result of immoral behavior.” (Table 7, bottom half).  Remarkably, 
72% of respondents ‘strongly agree’ or ‘agree’ that HIV is usually transmitted as 
a result of immoral behavior.  
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Respondent Answers     
      
“Are HIV tests in your clinic accurate or are they sometimes wrong?” 
      
Very Accurate   19% 
Accurate   70% 
Sometimes Wrong   11% 
Often Wrong   0% 
 
Table 7. Frequency of responses to the question “Are HIV tests in your clinic 
accurate or are they sometimes wrong?” The “tests” in question refer to ELISA 
serostatus tests for HIV (defined in the previous question respondents were 
asked).  
 
 
Respondent Answers     
      
“Using condoms is against God.“     
      
Strongly Agree   10% 
Agree   17% 
Disagree   39% 
Strongly Disagree   34% 
      
“People are usually infected with HIV through 
immoral behavior.”  
    
      
Strongly Agree   26% 
Agree   46% 
Disagree   18% 
Strongly Disagree   10% 
 
Table 8. Frequency of responses to questions that relate to religion, condom use, 
HIV transmission, and morality. 
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 Survey Responses by Category to Questions Regarding Why HIV is a 
Problem in Tanzania and Clinic Priorities.  Gender and locale effects were 
observed in responses to questions about why HIV is a problem in Tanzania and 
clinic priorities (Table 8) with the question, “Why is HIV a problem in 
Tanzania?” Fill-in responses to this question were remarkably similar, falling into 
four broad categories: ‘stigma’, ‘poverty’, ‘education’, and ‘other’.  A gender 
difference was observed among women answering this question. 15 females and 
37 males answered this question.  The mean response observed for women 
answering this question is 0.47 while the mean observed for men is 0.08.  Female 
respondents were approximately six times more likely than male respondents to 
choose stigma as an answer to this question (*p < .01).  
Conversely, gender differences were noticed in identifying education as a 
reason that HIV is a problem in Tanzania. 15 females and 37 males answered this 
question.  The mean response observed for women answering this question is 0.33 
while the mean observed for men is 0.78.  Men were more than twice as likely as 
women to choose education as an answer to this question (*p < .01).  
 Locale also played a role in the question “Why is HIV a problem in 
Tanzania?” 33 urban clinicians and 21 rural clinicians responded to this question. 
In an effect that approaches significance, respondents in urban clinics were almost 
5 times more likely than respondents in rural clinics to cite stigma as a reason that 
HIV is a problem in Tanzania (§p < .1).   
 Clinicians were surveyed for their priorities with the question, “Please 
rank in order of importance what would make the most difference for the 
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community you serve”. Respondents were given options that included ‘Better / 
less expensive malaria treatment’ or ‘Better / less expensive malaria testing, 
‘Better / less expensive HIV treatment’, ‘Better / less expensive viral load testing 
for HIV’, ‘Better / less expensive CD4 testing for HIV’, and two fill-in options to 
document priorities not listed.  Group differences were observed based on the 
clinic location, affiliation with the government, and corporate status (for-profit or 
not for-profit).  49 providers in urban clinics and 31 providers in rural clinics 
responded to this question. Providers in rural clinics were more than 3 times more 
likely than providers in urban clinics to cite ‘Better malaria treatment’ as the top 
priority (*p < .01).  
In an effect that approaches significance, providers in non-government 
clinics were more than twice as likely as providers in government clinics to cite 
‘Better malaria treatment’ as the top priority (§p < .1).  
 Finally, 36 respondents in for-profit clinics and 28 respondents in non-
profit clinics answered this question.  While not a strongly significant finding, 
respondents in for-profit clinics were more than 3 times as likely as respondents 
in non-profit clinics to cite HIV viral load as the top priority (§p < .1). 
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Question and Response by 
Category 
N Mean Sd Difference t 
         
“Why is HIV a problem in 
Tanzania?”  
  
   
  
Answered ‘Stigma’        
Male 37 0.08 0.28 -0.39 -3.5* 
Female 15 0.47 0.52   
Total 52     
      
Answered ‘Stigma’      
Urban 33 0.24 0.44 0.19 1.9§ 
Rural 21 0.05 0.22   
Total 54     
      
Answered ‘Education’       
Male 37 0.78 0.42 0.45 3.4* 
Female 15 0.33 0.49   
Total 52     
      
Clinic Priorities      
Malaria treatment as top priority      
Urban 49 0.12 0.33 -0.26 -2.9* 
Rural 31 0.39 0.50   
Total 80     
      
Malaria treatment as top priority      
Non-government clinic 58 0.28 0.45 .18 1.7§ 
Government clinic 21 0.10 0.30   
Total 79     
      
Viral load as top priority      
For-profit 36 0.25 0.44 0.18 1.9§ 
Not for-profit  28 0.07 0.26   
Total 64     
      
     §p < .1  *p < .01   
Table 9. Survey Responses by Category. Various responses to two questions were 
determined to be significant or to approach significance based on independent 
sampling t-tests.  The first question, “Why is HIV a problem in Tanzania?” drew 
gender and locale-based differences in responses. The next question, “Please rank 
in order of importance what would make the most difference for the community 
you serve”. Respondents were given options that included ‘Better / less expensive 
malaria treatment’ or ‘Better / less expensive malaria testing, ‘Better / less 
expensive HIV treatment’, ‘Better / less expensive viral load testing for HIV’, 
‘Better / less expensive CD4 testing for HIV’, and two fill-in options to document 
priorities not listed. 
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Mapped Locations of Several Arusha Town Medical Clinics.  A 
significant effort was undertaken to discover Arusha medical clinics. A private 
GoogleMap (Google) was created to dynamically add and adjust clinics as 
needed.  Maps were marked by hand until staff members could access internet 
services, at which point data was uploaded.   
 
 
 
 
Figure 9.  Mapped locations of several Arusha Town medical clinics. 
This map shows the location of some of the urban clinics included in the 
study. 
 
 
DISCUSSION  
 Communities in sub-Saharan Africa are in the midst of a healthcare crisis 
for PLWHA.  While significant progress has been made in the delivery of cART, 
most countries struggle to provide even the most basic health management tests: 
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the clinical determination of an appropriate start time for cART and monitoring to 
ensure efficacy of cART.  The viral load test in particular is not widely available 
in sub-Saharan Africa.  Because an inexpensive and rapid LAMP viral load 
diagnostic was developed at Arizona State University, this study was undertaken 
to evaluate barriers to adoption of LAMP or a similar technology in Northern 
Tanzania.  
 Working in developing countries presents challenges not faced in 
industrialized nations.  Finding medical providers to survey was a project unto 
itself.  Local knowledge was not sufficient to find local clinics.  It was not 
unusual to find local people who had lived in a community for their entire lives 
who did not know that a medical clinic was nearby. The same problem was also 
true of staff working at medical clinics.  Because snowball sampling produced 
modest results, mapping involved covering land surface area by driving hired 
cars, utilizing local transport (local buses), and hiking.  
 Medical clinics were mapped and surveyed for staff (Table 2) and services 
(Table 3).  Overall, an estimated 64% of clinics opted to participate in the study.  
Most of the clinic leaders shared that they were very willing to participate in the 
study.  The most common reasons for clinic non-participation were cost-limitation 
(limits to budget for survey collection and transport) and delay in completing the 
survey.  In several cases, project staff were asked to return repeatedly on 
subsequent days to pick up surveys only to find that the surveys had not yet been 
completed.  
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 Overall, an estimated 24% of providers in the area participated (Table 4). 
The most common reasons for provider non-participation were not being at work 
on the day of survey distribution and cost limitation (limits to budget for survey 
collection). The total number of providers in the area is a very difficult number to 
accurately cite.  Several medical providers have more than one posting.  
Moreover, many medical providers didn’t know the size of the staff at their place 
of employment, unless the clinic was very small.   
 Willingness to Adopt a New Viral Load Assay. The most basic question 
of the study asked whether medical providers would be willing to use a new viral 
load assay that produced results within an hour and cost 15,000 TSH per test 
(approximately $12 USD). 74.6% of providers indicated that they would not use 
such a test.  Based on accompanying comments from respondents who answered 
“No” to this question, providers feel that 15,000 TSH (approximately $12 USD) 
per test is too expensive.   
Interestingly, respondents who did not answer the Yes/No component of 
the question further elucidated the issue in their comments.  These providers 
indicated that the assay is not too expensive but that the question of who would 
pay for the test would determine whether or not they would be willing to use it.  If 
the government or an NGO would pay for the test and for the staff time spent 
conducting the test, they would be inclined to use the test.  
This concern highlighted other comments made by providers about 
government regulations.  They state that the government requires that many 
private clinics offer HIV testing and counseling.  While the government provides 
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free test reagents, there is no compensation for staff time or other ancillary 
expenses.  Because peri-urban and rural clinics are commonly understaffed, 
counseling for an HIV positive diagnosis means an impact in services for which 
the clinic generally receives income.  For this reason, there was a general 
resistance among clinic leaders in regard to accepting more equipment for HIV 
diagnostics.  For them, the implication is that if they have the equipment, they 
will be required to provide staff time for free viral load tests.  It is not clear from 
the data if this is effect is a consequence of social pressure or Ministry of Health 
regulation.  
 Patient-Provider Relationships. Free form participant responses to this 
and other questions about HIV services (data not shown) demonstrate that private 
medical clinics have exported responsibility for HIV and AIDS care to 
government treatment centers.  For example, the majority of providers did not 
answer a question about how many patients in their office are using antiretroviral 
therapy.  When a small clinic discovers an HIV positive case by ELISA, the 
patient is almost immediately referred to a regional treatment center.  
Patients who test positive in a clinic do not necessarily return later for any 
services.  In fact, the clinic may have been chosen for an HIV test specifically 
because it is relatively far away from the patients’ home community. In part, this 
can be accounted for by recognizing a difference between Tanzanian healthcare 
and healthcare provided in industrialized nations.  People living in rural Tanzania 
do not generally have the equivalent of a primary care physician (PCP), unless it 
is an unlicensed traditional healer who is a part of their home community.  A visit 
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to a western-style medical clinic is often the choice of last resort for rural 
Tanzanians seeking to heal a sickness that cannot be addressed by traditional 
means.  
Providers and Indications of Stigma. Another aspect of this issue deals 
with stigma. Medical providers’ responses to a question about HIV transmission 
and morality were recorded (Table 7).  72% of medical providers either agreed or 
strongly agreed that HIV is usually transmitted as a result of immoral behavior.  
The simple explanation that the majority of HIV transmission in Tanzania is 
sexual does not suffice to address this result. Another aspect of rapid patient turn-
over likely involves stigma against HIV and AIDS in Tanzania.  It has been 
shown that individuals prefer anonymous HIV testing so that they can make their 
own choice regarding public disclosure of status (108). Everyone suffers when 
medical providers believe that HIV transmission is largely immoral, to include 
female patients who have been infected by their husbands. 
Also surprising is that 89% of medical providers responded that ELISA 
tests are either accurate or very accurate.  ELISA tests are well-known to have a 
high rate of false positives.  In fact, in one study in East Africa, the rate of false 
positives was so high that it brought the positive predictive value of the test, a 
measure of the number of false positive compared to true positives, to 45.7% (7).  
It may be that because HIV-1 Western Blot testing is generally not available in 
Africa, clinicians believe that the ELISA test is of high enough quality that false 
positive results should generally not occur.    
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This finding is particularly problematic because it means that anyone who 
receives a positive result by ELISA is assumed to have received a true positive 
result.  When this result is considered in conjunction with the finding that most 
medical providers believe that HIV is usually transmitted as a result of immoral 
behavior, a problem becomes clear.  If patients sense judgment from healthcare 
workers, they may be less inclined to return for treatment.  Stigma against 
PLWHA may be more pervasive in Tanzania than is generally acknowledged.  
Responses about confidence in ELISA testing raises an issue regarding 
education for healthcare workers in Tanzania.  If healthcare workers were better 
informed, they may have responded differently to the question about ELISA and 
also about the utility of viral load testing.  It is difficult to imagine that healthcare 
workers would agree to taking a viral load test if they do not completely 
understand the clinical value of the test.  
Provider Attitudes About Condom Use. Also noteworthy are responses 
regarding condom use (Table 7).  Despite years of WHO Abstinence, Be Faithful, 
Use condoms (A-B-C, or in Tanzania, A-B-K) public health campaigns, and 
significant investment in prevention education courses, 28% of respondents 
agreed or strongly agreed that “condom use is against God”. It is well-
documented that religion plays a role in health and wellness for PLWHA in 
Africa. However, it may be useful to examine the role of religion in moderating 
attitude toward HIV among health workers and resultant patient outcomes in sub-
Saharan Africa. 
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Gender Differences in Responses.  Female respondents were 
approximately six times more likely than men to indicate that stigma is a reason 
why HIV is a problem in Tanzania.  There are many ways to interpret this result.  
The effect may be present among all women or simply medical providers.  If it is 
a result that occurs among all women, one explanation is that it is an outcome of 
differentials in expectations relating to gender roles in Tanzania.  Broadly, women 
are expected to adhere to strict and traditional behavioral norms.  One of those 
norms relates to the necessity of sexual debut after marriage. If a woman is 
infected with HIV, an assumption may be that she became HIV positive as a 
consequence of breaking traditional norms. More data is needed to determine if 
there is any factual basis for this speculation.  
Male respondents were more than twice as likely as female respondents to 
cite education as a reason that HIV is a problem in Tanzania. Without additional 
data, it is difficult to draw a conclusion from this finding.  It may be that men 
have greater access to education and are socialized to place greater value on 
education than women.  
A surprising finding is that rural clinicians were almost 5 times less likely 
than urban clinics to cite stigma as a reason that HIV is a problem in Tanzania.  
This result is inconsistent with the conventional thinking that stigma is more 
severe in rural areas, where people have less awareness and education.  More data 
is needed to further develop this finding.  
Respondents in rural clinics were significantly more likely to cite ‘Better 
malaria treatment’ than respondents in urban clinics as the top priority. This 
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finding too requires further data for analysis.  One possibility is that urban 
government hospitals provide inexpensive or free malaria care, creating the 
condition that providers in urban clinics would not experience significant malaria 
case loads. Rural clinics, however would need to provide treatment for people 
who are very ill and incapable of making a journey into the city for treatment.  
Limitations and Considerations. The ethics of working in developing 
nations can be complicated.  On two occasions, Tanzanian project staff were not 
able to meet project timelines for goals.  Consequently, Americans were sent to 
work with staff to bring the project back on time.  While our research goal in 
Tanzania is capacity-building, we found ourselves in the position of having 
Americans solving local problems.  Upon arrival in Tanzania, it was observed that 
one staff member, a Tanzanian woman, was not able to make as much progress as 
was expected in collecting surveys owing to the amount of time she spent waiting 
in clinics to see the doctor in charge.  By contrast, two Americans had the 
opposite experience: despite asking to wait until sick patients were seen, doctors 
demanded that team members sit with them to talk about the research project 
ahead of sick patients. Various strategies were employed to minimize disruption 
of health services with little success.   
One approach to address this issue of privilege is to provide more 
structural support for local researcher in future research projects.  For example, 
project leaders could solicit an introduction letter from the Ministry of Health or 
from a regional medical officer so that local project coordinators are better able to 
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coordinate meetings with medical providers that do not adversely impact patient 
health.  
Another approach includes more training for local project coordinators to 
encourage Community Based Participatory Research (CBPR) methods.  With 
more education, a larger professional network, and good mentorship, it may be 
that local coordinators develop capacity to engage research work with innovation 
through a community of supporters despite gendered cultural constraints. 
This study was limited by the number of participants.  While there was 
broad support for the project among medical providers, it was not cost-effective to 
travel to several rural areas to drop-off and pick-up surveys.  
Conclusion. In light of the international progress made in designing and 
adapting RT-LAMP and other low-cost diagnostics for use resource-limited 
settings, it is important to consider a new testing and treatment paradigm for HIV-
1.  Generally, industrialized nations favor medical models that require patients to 
travel to medical centers for care.  Only in the event of a medical emergency are 
trained personnel dispatched to provide services in remote locations.  In contrast, 
medical models in developing countries that rely on Community Healthcare 
Workers (CHWs) and rural service networks have proven to be far more effective 
than centralized service systems.  
The point-of-need, flexible and mobile in industrialized nations is far less 
resilient in developing nations.  As an example, people living in rural areas of 
Northern Tanzania faced with health emergencies frequently have little recourse 
to centralized health services.  Transportation barriers and delays in service 
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combined with a lack of resources to overcome these barriers contribute to a 
continued rural-urban health divide in which people who live in urban areas have 
greater access to health services.  
In Tanzania, health services for HIV have been almost wholly exported to 
regional treatment centers.  As a result, there is a very thin layer of HIV services 
provided by private and public clinicians. Relegated to referring patients to 
regional centers following ELISA testing, the large majority of clinicians in the 
country can contribute to the national burden of HIV/AIDS care and treatment in 
very limited ways.  
Empowering all public and private clinicians to provide additional basic 
health management tests for HIV/AIDS represents a new paradigm for clinician 
involvement in HIV/AIDS testing and treatment in Tanzania. This paradigm 
might provide added benefits, including improved clinician efficacy, reduced 
patient populations at regional centers, and improved continuity of care.  
Qualitative or binary quantitative tests for HIV disease management are a central 
component of this approach. Public and private clinicians empowered with new 
capability to manage patient HIV/AIDS care could contribute meaningfully to 
reducing the public health burden of HIV in Tanzania.  
This approach also suggests an alternative protocol for clinicians working 
with HIV positive patients at the point-of-need.  Clinicians would utilize HIV-1 
RT-LAMP as a viral load screening assay.  Test results would indicate simply that 
a patient is either effectively suppressing HIV-1 replication or not effectively 
suppressing replication.  Given this information, clinicians at the point-of-need 
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can be more involved in assisting patients with drug side-effect or adherence 
problems.  In the event that a screening test result indicates virologic failure, 
clinicians may continue to refer patients to regional centers for quantitative testing 
and more comprehensive care. 
The mixed-method approach undertaken in this study yielded valuable 
results not otherwise available through monomethod designs.  It was initial 
investigations into the health status of HIV positive women living in Tanzania in 
2005 that made clear the problem of viral load price and availability.  Only after 
the issue was discovered among a cohort of 40 HIV positive women in Tanzania 
did a literature search reveal a broader viral load problem in sub-Saharan Africa.   
The design and development of the RT-LAMP assay was based on 
literature reviews and a traditional molecular biology approach. However, input 
was periodically sought from collaborators and partners abroad in Africa during 
development.  The idea that LAMP could be used as a qualitative screen, for 
example, came as a result of conversations with collaborators and partners. 
Further, the findings from the survey of medical providers indicate that 
technology alone is not a solution to the problem of viral load assays in sub-
Saharan Africa. Respondents indicated that economics would play a significant 
role in assay adoption. This finding informs our approach for next steps: instead 
of installing proof-of-concept LAMP kits at various clinics and providing 
training, we can seek a partner willing to fund a larger investigation of RT-LAMP 
in sub-Saharan Africa.  
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Mixed-method approaches afford researchers an opportunity to forge 
interdisciplinary collaborations and to learn about connected fields. Leveraging 
the strengths of an interdisciplinary research team, researchers learn theory, skills, 
and techniques to which they would not otherwise have been exposed.  Moreover, 
researchers participating in mixed-methods approaches may have the opportunity 
to build larger networks than researchers utilizing monomethod approaches. 
Larger networks may mean more research or funding opportunities.  
Utilizing a mixed-methods approach in a graduate thesis has drawbacks.  
An important aspect of graduate education is the leveraging of expertise that takes 
place when students can focus on a tightly related set of research methods.  It is 
more difficult to achieve mastery of research methods and techniques when 
attention is divided between core techniques and methods that are part of 
interdisciplinary science. 
The HIV-1 RT-LAMP assay developed for low-income countries and 
accompanying survey represents a step forward for “Lab-to-Village” HIV-1 
diagnostic technology development efforts.  The mixed-methods approach 
utilized included rational engineering design in conjunction with cultural 
evaluation to facilitate technology transfer to resource-limited settings.  An 
important consideration for researchers is a systems-based approach to 
engineering design and cultural evaluation.  By incorporating cultural evaluation 
into the design process, results can inform the direction of the development 
process. Indeed, while basic technical specifications were met in the laboratory 
for a proof-of-concept RT-LAMP assay that could be used in developing 
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countries, unexpected and complex responses from medical providers in Tanzania 
indicate that far more must be done to ensure that this new technology finds ready 
hands. 
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